{"meta":{"query_hash":"9ccf8b315765","filters":{"venue":"Therapeutic Advances in Medical Oncology"},"cohort_total":84,"direct_labels_cover":0,"predictions_cover":84,"exported":84,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/9ccf8b315765","api":"https://metacan.xera.ac/api/v1/cohort?venue=Therapeutic+Advances+in+Medical+Oncology"},"results":[{"id":"W2086837512","doi":"10.1177/1758834012475152","title":"Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects","year":2013,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Medicine; Breast cancer; Immunotherapy; Immune system; Cancer research; Immune checkpoint; Tumor-infiltrating lymphocytes; Estrogen receptor; Cancer; Immunology; Oncology; Internal medicine","score_opus":0.08073664781397404,"score_gpt":0.4189070756368191,"score_spread":0.33817042782284507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086837512","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015973483,0.99492973,0.00060379005,0.0015958666,0.00016926292,0.000013265309,0.000012965856,0.000015361988,0.0010623953],"genre_scores_gemma":[0.008719054,0.9878929,0.0013129426,0.0010129097,0.0005806561,0.000031611467,0.000043575044,0.0000056441327,0.000400655],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996853,0.000085213236,0.000045295783,0.000043598473,0.00008486871,0.000055833378],"domain_scores_gemma":[0.9991516,0.00048761108,0.00010028419,0.000029952738,0.00014285359,0.000087787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023503217,0.0007035402,0.0012159866,0.0008457973,0.00024728378,0.0013779826,0.00069506746,0.001463078,0.0017836018],"category_scores_gemma":[0.0011359499,0.00022771867,0.00061388896,0.0010632003,0.00086965284,0.0016912217,0.00059231237,0.0022801221,0.0006703885],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004886143,0.00065188133,0.0007282401,0.00453364,0.00009901256,0.00038696834,0.00012122842,0.00080113683,0.008761547,0.0035598695,0.00984991,0.970018],"study_design_scores_gemma":[0.0009870514,0.008163874,0.01059342,0.011169669,0.00088185346,0.008043037,0.00087908504,0.0029558598,0.0118737845,0.017072178,0.92725664,0.00012359263],"about_ca_topic_score_codex":0.00030976767,"about_ca_topic_score_gemma":0.00088979385,"teacher_disagreement_score":0.0023503217,"about_ca_system_score_codex":0.00041821742,"about_ca_system_score_gemma":0.0006231127,"threshold_uncertainty_score":0.012429833},"labels":[],"label_agreement":null},{"id":"W2105738161","doi":"10.1177/1758834010374727","title":"Highlights of the 2nd European Lung Cancer Conference","year":2010,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Internal medicine","score_opus":0.015730350520810843,"score_gpt":0.41357133399359536,"score_spread":0.3978409834727845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105738161","genre_codex":"editorial","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003329186,0.093240626,0.0014454382,0.39883536,0.46981373,0.0003490413,0.0014758578,0.00015141981,0.031359296],"genre_scores_gemma":[0.043498855,0.08696788,0.0039223614,0.1928174,0.44888583,0.0009137715,0.0040066293,0.00032107276,0.21866614],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996442,0.00065455126,0.0002304127,0.00043015077,0.0015371579,0.00070563494],"domain_scores_gemma":[0.9941338,0.00072583073,0.00033676776,0.00012683347,0.0021450638,0.0025317692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013032439,0.0018449287,0.0011749022,0.0014479961,0.0016891893,0.005949439,0.0020689573,0.01000336,0.012570244],"category_scores_gemma":[0.0067338557,0.00042548386,0.0018819253,0.0008750174,0.00092284335,0.0025277645,0.0025035765,0.0094636865,0.005979432],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003313697,0.00012499567,0.00034659452,0.0003112034,0.000036143232,0.00033126384,0.000041082585,0.00028713205,0.0004578343,0.0012460344,0.9634438,0.03304253],"study_design_scores_gemma":[0.00007447473,0.0000795927,0.0014155442,0.00024394674,0.000027200407,0.0001965219,0.00006797376,0.00011595788,0.0005055012,0.00072754,0.9965243,0.000021434062],"about_ca_topic_score_codex":0.0031676858,"about_ca_topic_score_gemma":0.007567824,"teacher_disagreement_score":0.013032439,"about_ca_system_score_codex":0.0040241233,"about_ca_system_score_gemma":0.0066882786,"threshold_uncertainty_score":0.06892294},"labels":[],"label_agreement":null},{"id":"W2111842868","doi":"10.1177/1758834011422556","title":"An overview of the c-MET signaling pathway","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":864,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Signal transduction; Hepatocyte growth factor; Receptor tyrosine kinase; Cancer research; Medicine; Tyrosine kinase; Cell biology; C-Met; Motility; Receptor; Biology; Internal medicine","score_opus":0.10909985669006583,"score_gpt":0.41079953937097025,"score_spread":0.3016996826809044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111842868","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00273409,0.9673305,0.005720564,0.001862441,0.00090214296,0.000041601226,0.00027373483,0.00015375706,0.02098111],"genre_scores_gemma":[0.0059287366,0.97837424,0.0056320066,0.0006693278,0.00079230807,0.00003793255,0.000442818,0.000012824214,0.008109881],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998541,0.000016890825,0.000016966153,0.000022736805,0.00006494605,0.00002435384],"domain_scores_gemma":[0.99991465,0.000018341207,0.000010733283,0.000002674463,0.000030883697,0.000022783159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021844108,0.0007463376,0.0004994565,0.0019626494,0.00029932996,0.00095529994,0.0004972038,0.0007591083,0.005642754],"category_scores_gemma":[0.00019338679,0.00023334422,0.00037827116,0.0016051854,0.00015848925,0.0010836347,0.00044875705,0.0011962423,0.0035112682],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028115328,0.00013665357,0.00061885256,0.0043846155,0.000060611794,0.00081349735,0.000059782935,0.0011901197,0.024527712,0.006482165,0.041451532,0.9199933],"study_design_scores_gemma":[0.00001580621,0.00018337334,0.0011568945,0.0006985296,0.000053627526,0.0028149027,0.000050487386,0.0004356041,0.0035572944,0.0034229832,0.9875907,0.000019811045],"about_ca_topic_score_codex":0.0010679337,"about_ca_topic_score_gemma":0.0014266125,"teacher_disagreement_score":0.005642754,"about_ca_system_score_codex":0.0005834458,"about_ca_system_score_gemma":0.0008652119,"threshold_uncertainty_score":0.01887685},"labels":[],"label_agreement":null},{"id":"W2113562909","doi":"10.1177/1758834009352498","title":"Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Temsirolimus; Pazopanib; Medicine; Axitinib; Sorafenib; Sunitinib; Bevacizumab; Everolimus; Renal cell carcinoma; Targeted therapy; Oncology; PI3K/AKT/mTOR pathway; Adjuvant; Clinical trial; Vascular endothelial growth factor; Adjuvant therapy; Internal medicine; Pharmacology; Discovery and development of mTOR inhibitors; Cancer; VEGF receptors; Chemotherapy","score_opus":0.03495072061428077,"score_gpt":0.38143006076980135,"score_spread":0.34647934015552057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113562909","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009525067,0.991996,0.00020231579,0.0030477452,0.0031850727,0.000017370505,0.00002971118,0.000013958831,0.0014125381],"genre_scores_gemma":[0.00056247826,0.99256927,0.00029860268,0.002260898,0.0028934525,0.000020634534,0.00004949514,0.0000039249976,0.001341298],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995271,0.00015824083,0.00007507022,0.000053128835,0.00015509024,0.000031350708],"domain_scores_gemma":[0.9986234,0.00064274255,0.00014223243,0.000026499212,0.00042369982,0.00014150588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011362366,0.0010484603,0.0022399812,0.0016327741,0.00039149314,0.0014183235,0.001556379,0.0022055001,0.009713172],"category_scores_gemma":[0.0022430301,0.00021225134,0.0006933933,0.0023585742,0.0006979041,0.0025780408,0.0005168979,0.0021718536,0.006410961],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020798479,0.00008383558,0.00020197777,0.013764397,0.00010007076,0.00038015738,0.00003152884,0.00033934944,0.00053175114,0.001182114,0.3207904,0.66238636],"study_design_scores_gemma":[0.000080253536,0.00013522015,0.0008439049,0.005158461,0.00014591921,0.002202554,0.000058727514,0.00010702079,0.00011837291,0.0013714196,0.98976,0.000018204564],"about_ca_topic_score_codex":0.0011869372,"about_ca_topic_score_gemma":0.0024205511,"teacher_disagreement_score":0.009713172,"about_ca_system_score_codex":0.00082600256,"about_ca_system_score_gemma":0.0013160645,"threshold_uncertainty_score":0.03249383},"labels":[],"label_agreement":null},{"id":"W2118364274","doi":"10.1177/1758834012438214","title":"Exemestane in the prevention setting","year":2012,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Exemestane; Medicine; Breast cancer; Aromatase; Oncology; Adjuvant; Internal medicine; Clinical trial; Cancer; Gynecology","score_opus":0.010534767533464436,"score_gpt":0.35654649660876714,"score_spread":0.3460117290753027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118364274","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0064062504,0.9746249,0.0008778271,0.0043036677,0.00055640476,0.000017906348,0.000075832795,0.000019674753,0.013117605],"genre_scores_gemma":[0.095564544,0.88797337,0.002301033,0.004210174,0.0023702804,0.00003473081,0.00012721375,0.00001042809,0.00740825],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99978226,0.0000831018,0.0000309257,0.000028385297,0.000058334346,0.000017066892],"domain_scores_gemma":[0.9995546,0.00022979786,0.00010818577,0.000016753687,0.000052188498,0.000038464066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004647118,0.00016624662,0.0003611937,0.00035729408,0.000191802,0.0005840787,0.0002381245,0.00061976485,0.0026839452],"category_scores_gemma":[0.0009839502,0.00008349047,0.000277473,0.00030300577,0.00021340112,0.0005417693,0.0002970463,0.0009979036,0.0009497576],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011624191,0.00019400312,0.0038159187,0.005754329,0.00011004707,0.0026225615,0.00017823215,0.0003128477,0.008346501,0.011905204,0.017970772,0.9476272],"study_design_scores_gemma":[0.00022628243,0.0011060855,0.006090835,0.0038509578,0.00025916056,0.01591906,0.00019522994,0.00015064245,0.008834872,0.009147926,0.95419186,0.000027146549],"about_ca_topic_score_codex":0.00028222828,"about_ca_topic_score_gemma":0.00065168424,"teacher_disagreement_score":0.0026839452,"about_ca_system_score_codex":0.00026670916,"about_ca_system_score_gemma":0.0005499463,"threshold_uncertainty_score":0.008978665},"labels":[],"label_agreement":null},{"id":"W2122895515","doi":"10.1177/1758834011422557","title":"c-MET as a potential therapeutic target and biomarker in cancer","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Hepatocyte growth factor; C-Met; Cancer research; Receptor tyrosine kinase; Cabozantinib; Angiogenesis; Tyrosine kinase; Cancer; Targeted therapy; Oncology; Internal medicine; Receptor; VEGF receptors","score_opus":0.042716451349543764,"score_gpt":0.38644154722704865,"score_spread":0.3437250958775049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122895515","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022021731,0.95973414,0.0053175683,0.0052004266,0.0005753123,0.000033471995,0.00008187507,0.00006697377,0.0069684335],"genre_scores_gemma":[0.35579512,0.6168975,0.016528152,0.0021265612,0.002086367,0.00007096607,0.00025236147,0.000019986377,0.0062229787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998048,0.000067592766,0.000014592791,0.000022614933,0.000070205635,0.000020325902],"domain_scores_gemma":[0.9998222,0.00007306167,0.00003365778,0.0000065461554,0.000036057492,0.000028439053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000626042,0.000337207,0.00055905356,0.00091454433,0.00015822712,0.0007016965,0.0003780044,0.0008746805,0.0011854661],"category_scores_gemma":[0.0005488013,0.00010758896,0.00014648827,0.0007280938,0.00043791698,0.00062645954,0.00030457467,0.00068815175,0.00040321698],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010903352,0.00020339152,0.006747376,0.004241791,0.00008612854,0.0026511778,0.00013081222,0.0017898361,0.14696726,0.02206151,0.011312123,0.80271834],"study_design_scores_gemma":[0.00021441304,0.004555997,0.026814051,0.0017510392,0.00040226456,0.024101287,0.00039176818,0.01143473,0.17521384,0.027754778,0.72722125,0.00014453873],"about_ca_topic_score_codex":0.0004434879,"about_ca_topic_score_gemma":0.0006100278,"teacher_disagreement_score":0.0011854661,"about_ca_system_score_codex":0.0005294626,"about_ca_system_score_gemma":0.00054779404,"threshold_uncertainty_score":0.003965795},"labels":[],"label_agreement":null},{"id":"W2139562398","doi":"10.1177/1758834010395342","title":"Health-related quality of life and cancer clinical trials","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Clinical trial; Cancer; Quality of life (healthcare); Quality (philosophy); Intensive care medicine; Oncology; Internal medicine; Nursing","score_opus":0.299585135842967,"score_gpt":0.554391340122369,"score_spread":0.25480620427940204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139562398","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0067186453,0.9283584,0.0045051915,0.032741632,0.0057919286,0.0029120743,0.003123592,0.000092019945,0.015756508],"genre_scores_gemma":[0.3633525,0.48137775,0.01970608,0.06455564,0.01519719,0.04146266,0.007231333,0.00034331568,0.0067735454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.583081,0.36327335,0.025731789,0.007732948,0.017794512,0.0023864994],"domain_scores_gemma":[0.36893326,0.5232136,0.07538163,0.010233134,0.015397062,0.006841314],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.19591944,0.0012970391,0.0077964845,0.004698624,0.0014241107,0.008147531,0.0023664886,0.008445891,0.020422697],"category_scores_gemma":[0.46690798,0.0005809762,0.0046761506,0.014241498,0.004126196,0.0051371153,0.0033818944,0.007607936,0.0027236987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04607165,0.001449502,0.04350242,0.1964848,0.04203283,0.0003621423,0.00091345736,0.0048961025,0.00017103145,0.07556467,0.12668559,0.46186584],"study_design_scores_gemma":[0.046951573,0.017746326,0.09040885,0.20869087,0.023230737,0.0014025839,0.0014341058,0.007818284,0.00044140618,0.25055236,0.3506208,0.0007020451],"about_ca_topic_score_codex":0.0014081857,"about_ca_topic_score_gemma":0.001088586,"teacher_disagreement_score":0.19591944,"about_ca_system_score_codex":0.007863929,"about_ca_system_score_gemma":0.0094294865,"threshold_uncertainty_score":0.99157447},"labels":[],"label_agreement":null},{"id":"W2156077273","doi":"10.1177/1758834009358417","title":"Renal cell carcinoma bone metastases: clinical advances","year":2010,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Zoledronic acid; Oncology; Systemic therapy; Targeted therapy; Bone disease; Clinical trial; Kidney cancer; Internal medicine; Cancer; Breast cancer; Osteoporosis","score_opus":0.04202467694925865,"score_gpt":0.4341992174272958,"score_spread":0.3921745404780371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156077273","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006891788,0.9747328,0.001256035,0.006701741,0.0005802349,0.00004274636,0.00010377895,0.000048203827,0.009642751],"genre_scores_gemma":[0.07631319,0.9105529,0.0038593123,0.0035854175,0.002839908,0.00003960528,0.00031966763,0.000016521055,0.0024734905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962604,0.00008051837,0.00005033409,0.000051641862,0.00015578498,0.00003579164],"domain_scores_gemma":[0.9987435,0.0005357907,0.00015194721,0.00006338259,0.00036715248,0.00013827841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020101508,0.00038655984,0.00061153376,0.0007734096,0.00021584917,0.0011960936,0.0004997306,0.00081214175,0.002265889],"category_scores_gemma":[0.0020724316,0.0001315541,0.00041659517,0.0011923199,0.00053954,0.0010869959,0.00041140802,0.0012000541,0.0007930329],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029889142,0.00018265362,0.0028688745,0.002089228,0.000054037326,0.0005011582,0.00007357379,0.0003181088,0.0026626454,0.0026603101,0.0108340485,0.9774564],"study_design_scores_gemma":[0.00032890032,0.0030848377,0.020445831,0.00307982,0.00041042108,0.01024179,0.00026810545,0.0011466739,0.0070710657,0.005277128,0.94858634,0.000059095135],"about_ca_topic_score_codex":0.000895768,"about_ca_topic_score_gemma":0.0022945395,"teacher_disagreement_score":0.002265889,"about_ca_system_score_codex":0.00058645284,"about_ca_system_score_gemma":0.0013785457,"threshold_uncertainty_score":0.010630846},"labels":[],"label_agreement":null},{"id":"W2166720958","doi":"10.1177/1758834011399306","title":"Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; Lung cancer; Regimen; Oncology; Maintenance therapy; Intensive care medicine; Chemotherapy; Immunotherapy; Disease; Internal medicine; Clinical trial; Cancer; Adverse effect","score_opus":0.018753666172804957,"score_gpt":0.3790955163536733,"score_spread":0.36034185018086834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166720958","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91269183,0.08125783,0.0010101164,0.0010747324,0.000053010066,0.00014403297,0.00025561234,0.00004302768,0.0034699251],"genre_scores_gemma":[0.98573166,0.011528376,0.0007627854,0.00048415543,0.00011103199,0.000067990986,0.000448409,0.000009287148,0.0008562595],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998357,0.00006330546,0.000018037048,0.000017824479,0.000043616554,0.000021468933],"domain_scores_gemma":[0.99962807,0.00013898272,0.000116617055,0.000023596245,0.000030453393,0.0000621839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008848314,0.00010919889,0.0005467776,0.00016471562,0.00017076755,0.00030265583,0.00021543508,0.0003077636,0.00079454604],"category_scores_gemma":[0.0007924599,0.000035605994,0.00034432954,0.00029349845,0.00013229466,0.00036540776,0.00013256237,0.0005537666,0.00013193047],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015809955,0.0019316904,0.04938954,0.000700867,0.00029839715,0.00047103263,0.0002759675,0.0011208344,0.022460938,0.0005808566,0.0024383632,0.9045216],"study_design_scores_gemma":[0.0055130515,0.20211568,0.7139797,0.00049887795,0.0011927211,0.00677509,0.0003130473,0.003958372,0.015908835,0.0021599822,0.047525622,0.000058936104],"about_ca_topic_score_codex":0.00032692662,"about_ca_topic_score_gemma":0.0008645131,"teacher_disagreement_score":0.0008848314,"about_ca_system_score_codex":0.00036055327,"about_ca_system_score_gemma":0.000192773,"threshold_uncertainty_score":0.004679501},"labels":[],"label_agreement":null},{"id":"W2610105293","doi":"10.1177/1758834017704329","title":"Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical Practice; Affect (linguistics); Lung cancer; Medical physics; Oncology; Intensive care medicine; Family medicine; Psychology","score_opus":0.31719594479789304,"score_gpt":0.5822947835792166,"score_spread":0.26509883878132356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610105293","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007611517,0.9983783,0.00010586629,0.00047513176,0.0001997138,0.000006471893,0.000042212672,0.0000055451987,0.0007106527],"genre_scores_gemma":[0.0005231223,0.9984842,0.00021353383,0.0003228517,0.00018469243,0.000008334769,0.00004005843,0.0000016097333,0.00022159604],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9995127,0.00012234025,0.00012455658,0.00006526911,0.00015226012,0.000022905777],"domain_scores_gemma":[0.99826473,0.0011524798,0.00022505615,0.000025890926,0.00028368106,0.000048242866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009945409,0.00065677555,0.0012270526,0.0035085345,0.0002527637,0.0008883541,0.00082087604,0.00094885944,0.0041818707],"category_scores_gemma":[0.0035575868,0.00028723612,0.00095638825,0.0028379422,0.00039958526,0.0011778403,0.0004835095,0.0013254869,0.0012378613],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007180168,0.00004733218,0.00043593324,0.056224104,0.00025185887,0.000235494,0.0001020311,0.0004049345,0.00048599162,0.002927809,0.052279774,0.88653284],"study_design_scores_gemma":[0.00002314613,0.00009835684,0.0021523344,0.03507784,0.0005302848,0.0023125457,0.00008978196,0.00013057506,0.00025517322,0.002298015,0.95699745,0.000034532983],"about_ca_topic_score_codex":0.0018150045,"about_ca_topic_score_gemma":0.003130044,"teacher_disagreement_score":0.0041818707,"about_ca_system_score_codex":0.00075137656,"about_ca_system_score_gemma":0.0017964183,"threshold_uncertainty_score":0.013989747},"labels":[],"label_agreement":null},{"id":"W2787639107","doi":"10.1177/1758834017753338","title":"Turning <i>EGFR</i> mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors","year":2018,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Osimertinib; Afatinib; Erlotinib; T790M; Gefitinib; Medicine; Lung cancer; Tolerability; Oncology; Epidermal growth factor receptor; Resistance mutation; Erlotinib Hydrochloride; Tyrosine kinase; Internal medicine; Cancer research; Cancer; Adverse effect; Biology; Receptor","score_opus":0.018763228355649305,"score_gpt":0.4154327985471971,"score_spread":0.3966695701915478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787639107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21593031,0.68647605,0.035373725,0.026655996,0.002459982,0.00030376404,0.00015824001,0.00036308914,0.03227882],"genre_scores_gemma":[0.6956035,0.26800355,0.022810029,0.0048408215,0.003530102,0.00018647383,0.00027865585,0.000060363356,0.0046864874],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984026,0.000044928056,0.000022186894,0.000020687068,0.00003696813,0.000034928926],"domain_scores_gemma":[0.9998535,0.000039399336,0.000040355982,0.0000058584005,0.000020178635,0.0000406919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041140922,0.00024298274,0.00050255965,0.00016316136,0.0001738086,0.0007772097,0.0002794778,0.0003937116,0.0007779948],"category_scores_gemma":[0.0005290045,0.000117768504,0.00028698702,0.00011613111,0.0002676979,0.00082913245,0.00041234464,0.0010791144,0.00032797336],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016654383,0.00069596834,0.00491534,0.0020307098,0.00013984244,0.0015976814,0.0002056837,0.0029889338,0.049118258,0.008296377,0.017948182,0.9103976],"study_design_scores_gemma":[0.0020002131,0.018346727,0.05220787,0.00431499,0.0009307414,0.030857325,0.0014740279,0.021289468,0.050137013,0.03702007,0.7812153,0.00020627354],"about_ca_topic_score_codex":0.0003033844,"about_ca_topic_score_gemma":0.0014249993,"teacher_disagreement_score":0.0007779948,"about_ca_system_score_codex":0.0003872505,"about_ca_system_score_gemma":0.00067869737,"threshold_uncertainty_score":0.0028097034},"labels":[],"label_agreement":null},{"id":"W2945349403","doi":"10.1177/1758835919850367","title":"Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine <i>versus</i> FOLFIRINOX in advanced pancreatic cancer: a systematic review","year":2019,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services","funders":"Celgene","keywords":"FOLFIRINOX; Medicine; Gemcitabine; Irinotecan; Internal medicine; Oxaliplatin; Neutropenia; Oncology; Pancreatic cancer; Gastroenterology; Cancer; Chemotherapy; Colorectal cancer","score_opus":0.11378650241791426,"score_gpt":0.5148520294269145,"score_spread":0.4010655270090003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945349403","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051531796,0.9926553,0.00020188726,0.00025652858,0.00012757206,0.0007944505,0.0004968122,0.000012080183,0.00030220486],"genre_scores_gemma":[0.09055014,0.903946,0.0016953059,0.0010467157,0.00018056216,0.0018517408,0.0005171848,0.000015132793,0.00019717835],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9853314,0.006233406,0.0056377216,0.0009156254,0.0015903305,0.00029154975],"domain_scores_gemma":[0.95735556,0.029073622,0.009405251,0.00064259546,0.0030307423,0.00049229583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014266958,0.0014091334,0.012054671,0.009164308,0.0006278528,0.003276662,0.0018617831,0.0019643314,0.0031413753],"category_scores_gemma":[0.04192007,0.0011506984,0.01025196,0.007999417,0.0011579909,0.002234119,0.0013715737,0.0011279066,0.00024156584],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072792335,0.000019772397,0.0008622037,0.95082283,0.03473044,0.00008476364,0.00014891358,0.000080684964,0.00021100817,0.00009942911,0.00036208695,0.0118499715],"study_design_scores_gemma":[0.0016538255,0.00090311136,0.0056330194,0.6579472,0.32406747,0.0003959038,0.00041028677,0.00016664447,0.00033444885,0.00027010398,0.0081611145,0.000056839875],"about_ca_topic_score_codex":0.0054017357,"about_ca_topic_score_gemma":0.017044367,"teacher_disagreement_score":0.014266958,"about_ca_system_score_codex":0.0043696347,"about_ca_system_score_gemma":0.009567787,"threshold_uncertainty_score":0.07545173},"labels":[],"label_agreement":null},{"id":"W2945903793","doi":"10.1177/1758835919846372","title":"FAM84B promotes prostate tumorigenesis through a network alteration","year":2019,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"Cancer Research Society","keywords":"DU145; Cancer research; Carcinogenesis; Prostate cancer; Cell growth; Biology; Metastasis; Cell cycle; Cell; Cancer; Medicine; Genetics; LNCaP","score_opus":0.02679852681546533,"score_gpt":0.39975956751888975,"score_spread":0.3729610407034244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945903793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98866385,0.0035966374,0.0038868473,0.0001864855,0.000024259458,0.000023673228,0.0018361751,0.00019886505,0.0015831393],"genre_scores_gemma":[0.9934308,0.0015533512,0.0018402715,0.0000665744,0.000008905312,0.000025937265,0.0016510772,0.00001629114,0.0014068909],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998795,0.000014456813,0.0000053811273,0.000041735104,0.000026365968,0.00003259534],"domain_scores_gemma":[0.9998832,0.000009768394,0.000058436122,0.000007907096,0.000015892547,0.00002493096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008500853,0.000366957,0.00022327625,0.00037138653,0.00024106908,0.00036251592,0.00014357768,0.00024318948,0.0021325813],"category_scores_gemma":[0.00010234093,0.00013427538,0.0004016897,0.00038957543,0.00015051744,0.00023654841,0.00034027296,0.00026271856,0.00036559315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005086137,0.00005311643,0.011822207,0.00025255218,0.000115631236,0.00025664456,0.000032354685,0.0008035881,0.97684723,0.0003741282,0.00037481208,0.008559068],"study_design_scores_gemma":[0.00008279976,0.0011643306,0.52177405,0.000091110844,0.000552402,0.0023763706,0.00032799074,0.019180065,0.429065,0.0016035996,0.023735791,0.00004647809],"about_ca_topic_score_codex":0.00082169706,"about_ca_topic_score_gemma":0.0008413518,"teacher_disagreement_score":0.0021325813,"about_ca_system_score_codex":0.00040772508,"about_ca_system_score_gemma":0.00025783182,"threshold_uncertainty_score":0.0071342587},"labels":[],"label_agreement":null},{"id":"W3001249325","doi":"10.1177/1758835919895756","title":"Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Anaplastic lymphoma kinase; Cancer research; ROS1; Epidermal growth factor receptor; Medicine; Mutation; Lung cancer; Anaplastic large-cell lymphoma; PI3K/AKT/mTOR pathway; ERBB3; Fusion gene; Protein kinase domain; Cancer; Lymphoma; Biology; Gene; Oncology; Signal transduction; Adenocarcinoma; Genetics; Immunology; Internal medicine","score_opus":0.01754185532272969,"score_gpt":0.38092515561861406,"score_spread":0.3633833002958844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001249325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002624527,0.9970469,0.00015046043,0.0002162256,0.00018736249,0.0000077327395,0.000041091556,0.000010550378,0.0020772044],"genre_scores_gemma":[0.00097603287,0.9974644,0.00016909768,0.00020004314,0.00008898941,0.000008202956,0.00006080177,0.0000019652916,0.001030447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999304,0.0000108595705,0.000009543379,0.0000130752405,0.000027017986,0.000009127222],"domain_scores_gemma":[0.99992,0.00003559565,0.000013293706,0.0000023687126,0.000020686133,0.000007874299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020081471,0.0004781571,0.00076146,0.0013789698,0.00015278145,0.00057234336,0.00039187903,0.0004999807,0.004039764],"category_scores_gemma":[0.00027641474,0.00013703648,0.00038831847,0.0011136938,0.00014195906,0.00064886373,0.00039189734,0.0009894525,0.0019936394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000736749,0.00007447186,0.000114514914,0.018115861,0.00009372338,0.00023759765,0.00004795553,0.00030059286,0.003500888,0.002880948,0.031263255,0.94329655],"study_design_scores_gemma":[0.000017340662,0.00011010635,0.00047020704,0.0025600346,0.00012158662,0.0014194772,0.00003104502,0.000075924814,0.0005846129,0.0010242502,0.9935753,0.000010064847],"about_ca_topic_score_codex":0.00044782294,"about_ca_topic_score_gemma":0.0011165779,"teacher_disagreement_score":0.004039764,"about_ca_system_score_codex":0.0002815709,"about_ca_system_score_gemma":0.00048111443,"threshold_uncertainty_score":0.01351434},"labels":[],"label_agreement":null},{"id":"W3009738710","doi":"10.1177/1758835920915299","title":"Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Servier; Ipsen Fund; NuCana","keywords":"Medicine; Internal medicine; Everolimus; Progression-free survival; Oncology; Prospective cohort study; Sample size determination; Chemotherapy","score_opus":0.05922102353235283,"score_gpt":0.4006608372262131,"score_spread":0.3414398136938603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009738710","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036108645,0.99531794,0.00022799373,0.00011688305,0.00006697725,0.000106809704,0.00039058636,0.000010766893,0.00015126095],"genre_scores_gemma":[0.14625046,0.8500857,0.0011682453,0.00070271647,0.0001676238,0.00049563585,0.00089131837,0.000019709016,0.00021857597],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99567634,0.0018509546,0.0013721533,0.0005168212,0.00044154286,0.00014229944],"domain_scores_gemma":[0.9888171,0.0076616677,0.0022386904,0.000286386,0.0008014314,0.00019476206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007185731,0.0017762935,0.01359762,0.005539886,0.000395131,0.0022077218,0.001701205,0.0014883874,0.0030499366],"category_scores_gemma":[0.014607129,0.0009301304,0.025161,0.0066327285,0.00045354114,0.0013165253,0.0009980163,0.0011623257,0.00026066168],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018093203,0.000032754826,0.0045652124,0.46293408,0.51636744,0.000158888,0.00007786489,0.0004586195,0.00028384,0.00009567612,0.00064360263,0.012572765],"study_design_scores_gemma":[0.00049308984,0.0002802014,0.0054228655,0.03602891,0.95481145,0.00017535742,0.000056575067,0.0001649069,0.00011466731,0.00014508543,0.002281338,0.000025437179],"about_ca_topic_score_codex":0.004457171,"about_ca_topic_score_gemma":0.01227076,"teacher_disagreement_score":0.01359762,"about_ca_system_score_codex":0.0016544502,"about_ca_system_score_gemma":0.0021825244,"threshold_uncertainty_score":0.038002193},"labels":[],"label_agreement":null},{"id":"W3010740851","doi":"10.1177/1758835920909091","title":"Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Mount Sinai Hospital; Dr. H. Bliss Murphy Cancer Centre; BC Cancer Agency","funders":"","keywords":"Atezolizumab; Medicine; Metastatic breast cancer; Pembrolizumab; Oncology; Internal medicine; Hazard ratio; Triple-negative breast cancer; Breast cancer; Population; Chemotherapy; Placebo; Progression-free survival; Clinical trial; Cancer; Immunotherapy; Confidence interval; Pathology","score_opus":0.026929382798199477,"score_gpt":0.4086304143515668,"score_spread":0.3817010315533673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010740851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002792042,0.99687684,0.000052146122,0.0023259998,0.00016483938,0.0000030890383,0.000014346709,0.0000033310412,0.00028016442],"genre_scores_gemma":[0.004869538,0.992243,0.0002219554,0.0018381623,0.00064274034,0.000009268918,0.00002679044,0.000002558809,0.00014603772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984352,0.0005450149,0.00032786196,0.00018420262,0.00043797822,0.00006963662],"domain_scores_gemma":[0.990308,0.0066441977,0.0012946343,0.0001368217,0.0013620193,0.00025437196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077314256,0.0005240154,0.002049763,0.0013866937,0.00027337144,0.0024756335,0.0010292326,0.0014237332,0.003089272],"category_scores_gemma":[0.009206142,0.00028927476,0.0012748988,0.0017326734,0.0010232091,0.0036121244,0.00083618116,0.0024156282,0.0005180879],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000749919,0.00006389444,0.00089139456,0.04079111,0.0005095015,0.00015885447,0.00016505574,0.00040330074,0.00071473065,0.003974649,0.013203718,0.93837386],"study_design_scores_gemma":[0.00072706287,0.0021253412,0.0067144316,0.111890376,0.003881885,0.0016426168,0.00095339847,0.00091718556,0.00082586514,0.015288557,0.8549328,0.00010049435],"about_ca_topic_score_codex":0.0010992775,"about_ca_topic_score_gemma":0.0030298291,"teacher_disagreement_score":0.0077314256,"about_ca_system_score_codex":0.0012104288,"about_ca_system_score_gemma":0.002834428,"threshold_uncertainty_score":0.04088813},"labels":[],"label_agreement":null},{"id":"W3011081636","doi":"10.1177/1758835920911229","title":"Widespread expression of Sonic hedgehog (Shh) and Nrf2 in patients treated with cisplatin predicts outcome in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; McGill University","funders":"","keywords":"Sonic hedgehog; Medicine; Cyclopamine; Cancer research; Clonogenic assay; Hedgehog; Cisplatin; Context (archaeology); Vismodegib; Cancer; Oncology; Head and neck squamous-cell carcinoma; Hedgehog signaling pathway; Head and neck cancer; Internal medicine; Chemotherapy; Cell; Biology; Signal transduction; Basal cell carcinoma","score_opus":0.02253777044378503,"score_gpt":0.33128670254536735,"score_spread":0.30874893210158233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011081636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985065,0.00043020706,0.00019581376,0.00003802421,0.000004354111,0.000009460292,0.00046196426,0.0000069850944,0.00034662176],"genre_scores_gemma":[0.99908674,0.00010570526,0.00011078715,0.000011195456,0.0000037978245,0.000007709582,0.00051485986,0.0000016482663,0.00015754605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998925,0.0000145604145,0.000016251684,0.000034201043,0.000022787975,0.000019745421],"domain_scores_gemma":[0.99969363,0.00005782163,0.00012307784,0.000019690875,0.000039725182,0.00006607715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021189668,0.0001258807,0.00022110733,0.00040061242,0.0001806217,0.00023987317,0.00016624694,0.000219656,0.0015289839],"category_scores_gemma":[0.0006124828,0.000079937694,0.00024566584,0.00033370833,0.0001638464,0.00019330253,0.00030516938,0.00024042248,0.00016449479],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048360458,0.000026153963,0.9897684,0.000029647346,0.000051779516,0.00009968149,0.000020448564,0.0001184733,0.0054432554,0.00001719882,0.00013825421,0.0038031263],"study_design_scores_gemma":[0.000007769907,0.00012576453,0.9974274,0.0000061622322,0.000060740742,0.00038488,0.000056058376,0.00032654326,0.0011347233,0.000051277093,0.00041634365,0.000002347183],"about_ca_topic_score_codex":0.00085974886,"about_ca_topic_score_gemma":0.001737673,"teacher_disagreement_score":0.0015289839,"about_ca_system_score_codex":0.00019423982,"about_ca_system_score_gemma":0.00022046757,"threshold_uncertainty_score":0.005114913},"labels":[],"label_agreement":null},{"id":"W3129833506","doi":"10.1177/1758835921992987","title":"Elevated risk of colorectal, liver, and pancreatic cancers among HCV, HBV and/or HIV (co)infected individuals in a population based cohort in Canada","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University; Vancouver General Hospital; University of Waterloo; BC Centre for Disease Control; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Medicine; Internal medicine; Hepatitis C virus; Pancreatic cancer; Colorectal cancer; Gastroenterology; Population; Cohort; Hazard ratio; Liver cancer; Hepatitis B virus; Hepatitis C; Cancer; Hepatitis B; Confidence interval; Immunology; Virus","score_opus":0.015118668587111741,"score_gpt":0.31980979425488204,"score_spread":0.3046911256677703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129833506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563724,0.0006253489,0.00010563808,0.00016558358,0.000007106067,0.000019449477,0.002188877,0.000011098002,0.0012396594],"genre_scores_gemma":[0.9982876,0.00045047325,0.00008885186,0.000034002875,0.00000283962,0.000004656015,0.00072951685,0.0000021901403,0.00039973808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999622,0.000023989778,0.00001949998,0.00007161253,0.00013612979,0.00012673793],"domain_scores_gemma":[0.9992829,0.00003379561,0.00016584205,0.000030396403,0.000243434,0.00024360958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025524432,0.0002674953,0.00031377765,0.00092058507,0.0015291563,0.0009793055,0.0005827767,0.00025922127,0.0016482726],"category_scores_gemma":[0.0006782202,0.00033803727,0.000392322,0.0021991043,0.00046814643,0.00018810082,0.0005749996,0.0005288291,0.00014464278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047341153,0.0000066657485,0.9981053,0.0000118870275,0.000033312695,0.00008025914,0.00013518844,0.000050282684,0.00017977203,0.000026862557,0.00026830082,0.0010547702],"study_design_scores_gemma":[0.000005046772,0.00001250051,0.9988643,0.000013184372,0.000030083378,0.00013852058,0.00030159546,0.00020658904,0.000044688324,0.000023373923,0.00035446408,0.0000056812664],"about_ca_topic_score_codex":0.97527,"about_ca_topic_score_gemma":0.9784812,"teacher_disagreement_score":0.024730027,"about_ca_system_score_codex":0.006934342,"about_ca_system_score_gemma":0.010871478,"threshold_uncertainty_score":0.0503124},"labels":[],"label_agreement":null},{"id":"W3139304883","doi":"10.1177/1758835921998586","title":"Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Myovant Sciences","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Adverse effect; Testosterone (patch); Management of prostate cancer; Internal medicine; Oncology; Gonadotropin-releasing hormone; Androgen; Androgen suppression; Cancer; Luteinizing hormone; Endocrinology; Hormone","score_opus":0.0585975078822475,"score_gpt":0.45452544383896826,"score_spread":0.39592793595672077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139304883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43551993,0.50316876,0.014310571,0.0065690815,0.0015753335,0.0011302962,0.0016800648,0.0016700138,0.03437592],"genre_scores_gemma":[0.803578,0.15692855,0.015231039,0.0056106243,0.0009644875,0.00050662004,0.0022900067,0.000100271885,0.014790465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999442,0.000011795784,0.000004950018,0.000011203515,0.000017903234,0.000009958276],"domain_scores_gemma":[0.99996877,0.0000035966625,0.000009574111,0.0000014675977,0.0000033297144,0.000013327777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110375906,0.00027139232,0.00033325367,0.00028561594,0.00017067151,0.00024168032,0.0002690843,0.00024945196,0.0018494064],"category_scores_gemma":[0.000100292404,0.00007316087,0.00036881742,0.00017744355,0.000132045,0.00023392831,0.0002835885,0.0008265521,0.00051651814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003122661,0.0011289173,0.0017179624,0.0024550813,0.00018994622,0.0010290238,0.00012214303,0.0006504675,0.051361624,0.001129459,0.015352192,0.9217406],"study_design_scores_gemma":[0.013978665,0.04588014,0.050402537,0.0011022147,0.0008204578,0.03748771,0.00020258526,0.004180839,0.04702637,0.0022212898,0.7964679,0.0002292162],"about_ca_topic_score_codex":0.00040471638,"about_ca_topic_score_gemma":0.0016011297,"teacher_disagreement_score":0.0018494064,"about_ca_system_score_codex":0.00017114868,"about_ca_system_score_gemma":0.0003108801,"threshold_uncertainty_score":0.0061869025},"labels":[],"label_agreement":null},{"id":"W3152514714","doi":"10.1177/17588359211010156","title":"Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Jubilee Hospital; Spinal Cord Injury BC","funders":"","keywords":"Pembrolizumab; Medicine; Adenocarcinoma; Pancreas; Lung cancer; Tumor microenvironment; Lung; Gemcitabine; Pathology; Pancreatic cancer; Chemotherapy; Immune system; Oncology; Immunotherapy; Cancer research; Internal medicine; Cancer; Immunology","score_opus":0.01879562548514577,"score_gpt":0.29419115280817876,"score_spread":0.27539552732303296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152514714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979625,0.00060270354,0.00072979974,0.000049636103,0.000004887465,0.000016493874,0.00002839639,0.000014364457,0.0005912906],"genre_scores_gemma":[0.9990386,0.00026968995,0.00044832245,0.00002025574,0.00001020039,0.0000052518726,0.000053978278,0.0000026600806,0.00015105456],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.9999325,0.000010890633,0.0000059917656,0.000020073892,0.000013255917,0.000017353994],"domain_scores_gemma":[0.99991643,0.000020117572,0.00001688453,0.000008628382,0.000009517897,0.000028406548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096648575,0.00022418241,0.00026864646,0.00033279587,0.0002922403,0.00031051575,0.00013013092,0.00030247352,0.00037732846],"category_scores_gemma":[0.00020539528,0.00013281377,0.00020598895,0.00014639611,0.00018357667,0.0001601237,0.00016528358,0.00029304603,0.00012240035],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094102364,0.00020257865,0.13509983,0.0001955734,0.00006960474,0.1652491,0.00031606643,0.00044088002,0.67563623,0.00021160244,0.00019819263,0.021439336],"study_design_scores_gemma":[0.00006987786,0.0010516288,0.34731957,0.000020299713,0.00021290104,0.45700812,0.0005258478,0.0059285266,0.18359134,0.0002659294,0.003985603,0.000020404232],"about_ca_topic_score_codex":0.0003679621,"about_ca_topic_score_gemma":0.0007003573,"teacher_disagreement_score":0.00037732846,"about_ca_system_score_codex":0.000199925,"about_ca_system_score_gemma":0.0001207043,"threshold_uncertainty_score":0.0014505982},"labels":[],"label_agreement":null},{"id":"W3172779990","doi":"10.1177/17588359211019675","title":"Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health; Queen's University; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Karl Landsteiner Privatuniversität für Gesundheitswissenschaften","keywords":"Medicine; Internal medicine; Brain metastasis; Lung cancer; Oncology; Adverse effect; Retrospective cohort study; Confidence interval; Population; Fusion gene; Cancer; Metastasis; Gene","score_opus":0.01930944574526549,"score_gpt":0.44439614040856573,"score_spread":0.42508669466330024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172779990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991924,0.00025074143,0.00005028894,0.000009415612,0.0000017494425,0.00001383103,0.00027486135,0.0000019438387,0.00020462694],"genre_scores_gemma":[0.99923277,0.00012316725,0.000030823223,0.000022149572,0.000005307008,0.000011955068,0.0005113051,0.0000014723416,0.000061015606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921155,0.00018325822,0.00013114284,0.00023185945,0.0001509537,0.0000912439],"domain_scores_gemma":[0.9985429,0.00033720493,0.0006932245,0.000121928075,0.00013334607,0.00017136613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000864635,0.00021583085,0.00044773516,0.0008172177,0.00034890184,0.00063887227,0.00025816192,0.00035296552,0.001034962],"category_scores_gemma":[0.001229222,0.0002693325,0.0005500669,0.0009849089,0.00031564388,0.00044886078,0.0004946525,0.00032663098,0.00023190919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051522505,0.000057263656,0.99698704,0.000017404822,0.00009365012,0.00028705678,0.00005922017,0.000061824554,0.00031663303,0.000015536814,0.00008243144,0.0015067158],"study_design_scores_gemma":[0.000046900386,0.00074158976,0.9963141,0.000011675909,0.00011180225,0.0015768517,0.0001900892,0.00026861328,0.00024402117,0.000017918648,0.00046908553,0.000007322307],"about_ca_topic_score_codex":0.0014782287,"about_ca_topic_score_gemma":0.0016634269,"teacher_disagreement_score":0.0014782287,"about_ca_system_score_codex":0.00031508374,"about_ca_system_score_gemma":0.00032807342,"threshold_uncertainty_score":0.0045726895},"labels":[],"label_agreement":null},{"id":"W3191554850","doi":"10.1177/17588359211036544","title":"IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Gemcitabine; Clinical endpoint; Oncology; Chemotherapy; Internal medicine; Tumor microenvironment; Cancer; Immunotherapy; Clinical trial; Nivolumab","score_opus":0.011651884807790922,"score_gpt":0.33780044466591547,"score_spread":0.3261485598581245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191554850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98509246,0.0035878685,0.00054129044,0.0010980552,0.0007221345,0.0046543363,0.0011524592,0.00018297926,0.002968434],"genre_scores_gemma":[0.9809124,0.0019604664,0.0018895924,0.0022647209,0.0006242116,0.005762038,0.0026696566,0.000042366475,0.0038746358],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991652,0.0004699127,0.000044304034,0.0001499867,0.00004751039,0.00012308543],"domain_scores_gemma":[0.99882907,0.00021095235,0.00024276554,0.00010203976,0.00006821458,0.00054691837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024363361,0.00212142,0.003065175,0.00054864236,0.0004301202,0.001580283,0.0013834349,0.0021474315,0.006543014],"category_scores_gemma":[0.001805133,0.0010214068,0.0020114637,0.00042421967,0.0014887743,0.0015829629,0.00063652237,0.0035474824,0.0014779269],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97045296,0.010625036,0.00093622867,0.00043711314,0.00067964796,0.000036702666,0.000047459016,0.0003943845,0.0037964052,0.00013561346,0.0009852177,0.011473272],"study_design_scores_gemma":[0.9011625,0.09551803,0.0014495412,0.000020845453,0.0003083042,0.000043027627,0.000019296662,0.00041035723,0.00031995995,0.000087309505,0.0006451154,0.00001573598],"about_ca_topic_score_codex":0.0007665218,"about_ca_topic_score_gemma":0.0017323599,"teacher_disagreement_score":0.006543014,"about_ca_system_score_codex":0.0010828968,"about_ca_system_score_gemma":0.0014668006,"threshold_uncertainty_score":0.021888554},"labels":[],"label_agreement":null},{"id":"W3195299022","doi":"10.1177/17588359211039052","title":"Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Urothelial carcinoma; Carcinoma; Cancer research; Oncology; Bladder cancer; Internal medicine; Cancer","score_opus":0.09591219510996234,"score_gpt":0.4072967351049521,"score_spread":0.3113845399949898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195299022","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013833222,0.9988092,0.000109923596,0.00015419924,0.00010396654,0.0000045920374,0.000010868797,0.000005116382,0.000663756],"genre_scores_gemma":[0.00066718314,0.99868125,0.00016301815,0.00012647866,0.000077518846,0.000004653455,0.000020188143,9.95413e-7,0.0002586669],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998406,0.000030966698,0.00002477376,0.000026617632,0.000058638063,0.00001836439],"domain_scores_gemma":[0.99983907,0.0000802955,0.000026148702,0.0000044574185,0.000038001865,0.000011970869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039720023,0.000588707,0.0009656914,0.0019081034,0.00022944108,0.00074427295,0.00062596117,0.00068042526,0.0031126237],"category_scores_gemma":[0.00048792732,0.00019384833,0.00063202815,0.0014045514,0.00031904812,0.00097524544,0.0005510227,0.0015523909,0.0010959159],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006390249,0.00007479035,0.00013686068,0.024454325,0.00009955193,0.00019962758,0.000067116154,0.00043414749,0.0022464048,0.0027669815,0.013657437,0.955799],"study_design_scores_gemma":[0.000028625649,0.00018490123,0.0011174418,0.007087573,0.00018810896,0.001818315,0.00008493723,0.00017899206,0.00069335615,0.0021164317,0.9864796,0.000021793432],"about_ca_topic_score_codex":0.0008201986,"about_ca_topic_score_gemma":0.0018776755,"teacher_disagreement_score":0.0031126237,"about_ca_system_score_codex":0.0004053946,"about_ca_system_score_gemma":0.00070605293,"threshold_uncertainty_score":0.010412753},"labels":[],"label_agreement":null},{"id":"W3195679999","doi":"10.1177/17588359211035959","title":"The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Molecular pathology; Subtyping; Medicine; Endometrial cancer; Molecular diagnostics; Targeted therapy; Bioinformatics; Molecular marker; Cancer; Oncology; Internal medicine; Computational biology; Pathology; Biology; Gene; Genetics; Computer science","score_opus":0.04628385487803262,"score_gpt":0.4449737521368726,"score_spread":0.39868989725884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195679999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008745155,0.99861026,0.00012539503,0.0004487328,0.00012960506,0.0000024100873,0.000009038788,0.000003942786,0.00058308296],"genre_scores_gemma":[0.0007823866,0.9983511,0.00022402203,0.0003090835,0.00014013714,0.0000042215765,0.000013616297,0.0000011896913,0.0001742718],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997434,0.00008047808,0.000034489163,0.000036686088,0.000082286526,0.000022712358],"domain_scores_gemma":[0.9993774,0.00039904015,0.000052484986,0.000015169062,0.00013109246,0.000024832141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097957,0.00051246764,0.0009774519,0.0017937628,0.0002338496,0.0011260058,0.0006195989,0.0009914176,0.001963839],"category_scores_gemma":[0.0014523324,0.00020862333,0.00053437415,0.0014816908,0.00062913226,0.0013623312,0.0006452648,0.00201794,0.00090797216],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052187872,0.000038860035,0.00022236528,0.013865524,0.00009191352,0.00017233161,0.00007454551,0.00044327334,0.0011928607,0.006053108,0.015182909,0.9626101],"study_design_scores_gemma":[0.000021932807,0.00012582484,0.0013313695,0.007444183,0.00016313983,0.0015007555,0.00010356447,0.00021499163,0.00052454293,0.0050058616,0.983538,0.00002596609],"about_ca_topic_score_codex":0.0012471224,"about_ca_topic_score_gemma":0.0024519733,"teacher_disagreement_score":0.001963839,"about_ca_system_score_codex":0.0006842884,"about_ca_system_score_gemma":0.0011191757,"threshold_uncertainty_score":0.006569624},"labels":[],"label_agreement":null},{"id":"W3199693232","doi":"10.1177/17588359211034708","title":"New approaches to first-line treatment of advanced renal cell carcinoma","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Exelixis","keywords":"Axitinib; Medicine; Nivolumab; Pazopanib; Pembrolizumab; Cabozantinib; Sunitinib; Ipilimumab; Renal cell carcinoma; Oncology; Tyrosine-kinase inhibitor; Internal medicine; Avelumab; Kidney cancer; Lenvatinib; Immunotherapy; Cancer","score_opus":0.16901093999069464,"score_gpt":0.39927029872998737,"score_spread":0.23025935873929274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199693232","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008084555,0.9985304,0.000114069,0.00019578147,0.00017023111,0.0000057593056,0.000017259481,0.000007385334,0.00087822654],"genre_scores_gemma":[0.00040527375,0.99872833,0.0001651213,0.00018370316,0.00012288151,0.0000061013975,0.000030319765,0.0000012450382,0.00035713526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999811,0.00003594746,0.000027189248,0.00003303733,0.000077619414,0.000015297848],"domain_scores_gemma":[0.9998248,0.00008105618,0.000028355122,0.0000056205417,0.000046108285,0.000014062582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050024025,0.00070960686,0.0010832946,0.0020624325,0.0002261222,0.0007619043,0.0006743958,0.00062996295,0.0037848423],"category_scores_gemma":[0.00047392273,0.0002110949,0.00063485565,0.0014381908,0.0003135758,0.0010104914,0.0005073649,0.0020831125,0.001825472],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000752878,0.00008527777,0.00010510512,0.021078037,0.000116710056,0.00013077326,0.000043683536,0.00032107648,0.0015415389,0.0037822353,0.027310992,0.9454093],"study_design_scores_gemma":[0.00003418083,0.0001254353,0.0005877698,0.0040369,0.00013430654,0.0008775824,0.00003009919,0.00009681064,0.00035050706,0.0015389585,0.99217296,0.00001462389],"about_ca_topic_score_codex":0.00082783104,"about_ca_topic_score_gemma":0.0022774304,"teacher_disagreement_score":0.0037848423,"about_ca_system_score_codex":0.00056925556,"about_ca_system_score_gemma":0.00083943235,"threshold_uncertainty_score":0.012661517},"labels":[],"label_agreement":null},{"id":"W3202940729","doi":"10.1177/17588359211047352","title":"Metastatic Urothelial Cancer: a rapidly changing treatment landscape","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Urothelial cancer; Immunotherapy; Clinical trial; Oncology; Chemotherapy; Disease; Cancer; Internal medicine; Intensive care medicine; Bladder cancer; Urothelial carcinoma","score_opus":0.06794330522167166,"score_gpt":0.45002674657035063,"score_spread":0.382083441348679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202940729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000098276265,0.99838865,0.00007695254,0.0006499646,0.0001639628,0.0000028998,0.000018812676,0.0000060575385,0.0005944901],"genre_scores_gemma":[0.00043641488,0.9988181,0.00010056596,0.0003201745,0.00012669808,0.0000030563065,0.000024106406,0.0000011253651,0.00016980193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997162,0.00007333384,0.000043566117,0.00004096344,0.0001027049,0.000023059127],"domain_scores_gemma":[0.999426,0.00030993484,0.00006494097,0.000012956313,0.00014736224,0.00003887982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081549416,0.0005030205,0.0013439097,0.0016019813,0.00027040386,0.0010962997,0.00065900764,0.00088187924,0.0033200635],"category_scores_gemma":[0.0010533234,0.00017765179,0.000551683,0.0018951956,0.00037270362,0.0013166318,0.00057690445,0.0017255684,0.0013361024],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006457269,0.000049232698,0.00018884739,0.026928661,0.00010101315,0.0001724104,0.00006404965,0.0003201298,0.0011044503,0.003860871,0.031102696,0.9360429],"study_design_scores_gemma":[0.000019795616,0.000120271114,0.0008013025,0.008121452,0.00017312879,0.0011566256,0.00008246883,0.000092832015,0.0002379189,0.0021407637,0.98703617,0.00001727629],"about_ca_topic_score_codex":0.00096181664,"about_ca_topic_score_gemma":0.0026766378,"teacher_disagreement_score":0.0033200635,"about_ca_system_score_codex":0.0006713626,"about_ca_system_score_gemma":0.0015151354,"threshold_uncertainty_score":0.0111067295},"labels":[],"label_agreement":null},{"id":"W3203798531","doi":"10.1177/17588359211039928","title":"ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Post-hoc analysis; Internal medicine; Placebo; Pembrolizumab; Hazard ratio; Hepatocellular carcinoma; Confidence interval; Hepatology; Gastroenterology; Liver function; Sorafenib; Cancer; Pathology","score_opus":0.018507011407171443,"score_gpt":0.2851676526289131,"score_spread":0.26666064122174166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203798531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973916,0.008874614,0.0025659814,0.0010683598,0.0015236249,0.004947658,0.0032922255,0.000329512,0.003482188],"genre_scores_gemma":[0.9877702,0.0012079729,0.0018281617,0.000770812,0.00073979393,0.003966359,0.0015339269,0.00006097255,0.0021217992],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99331635,0.004872047,0.00032812948,0.00071482896,0.00028945008,0.0004792229],"domain_scores_gemma":[0.99190885,0.0042917933,0.0018536481,0.00083532464,0.0004726079,0.00063773565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010130397,0.0026187007,0.0052822884,0.0005256971,0.00037323072,0.0019418916,0.0012322271,0.0015798963,0.007829404],"category_scores_gemma":[0.009147299,0.0008340553,0.008148788,0.000480043,0.0011361436,0.0013511145,0.0008002414,0.0032561836,0.0007451639],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98681056,0.0007698627,0.00075288746,0.00051402696,0.0072021093,0.000021140364,0.000013969823,0.00030906702,0.0005140209,0.000055388628,0.00044312127,0.002593818],"study_design_scores_gemma":[0.88853776,0.0839135,0.0066622244,0.000088971115,0.01662585,0.000049306786,0.000031767042,0.0017229293,0.0010140631,0.00033093462,0.000981134,0.000041533185],"about_ca_topic_score_codex":0.00066156784,"about_ca_topic_score_gemma":0.00094058126,"teacher_disagreement_score":0.010130397,"about_ca_system_score_codex":0.0011847261,"about_ca_system_score_gemma":0.001467057,"threshold_uncertainty_score":0.053575277},"labels":[],"label_agreement":null},{"id":"W3208960913","doi":"10.1177/17588359211051870","title":"Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Systemic therapy; Hormone therapy; Internal medicine; Clinical trial; Radiation therapy; Prostate-specific antigen; Disease; Cancer; Breast cancer","score_opus":0.10205391747517757,"score_gpt":0.459568545127229,"score_spread":0.35751462765205144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208960913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008500451,0.99854136,0.000047100188,0.0006692614,0.00019482737,0.0000032087005,0.00001174677,0.0000028758518,0.00044457635],"genre_scores_gemma":[0.00075736514,0.9977011,0.00015537544,0.0007477389,0.00026032506,0.0000064321594,0.000025334271,0.0000014524506,0.00034494503],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978787,0.00006719904,0.00003440479,0.000027594164,0.00006600484,0.000016913125],"domain_scores_gemma":[0.9995827,0.00023035333,0.00006594241,0.000011635542,0.000085535525,0.000023891916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076992664,0.00041811934,0.001541209,0.0011211064,0.00020802449,0.000778784,0.0007894013,0.0011887936,0.0039535253],"category_scores_gemma":[0.0012409473,0.00017956889,0.0007611753,0.0010620361,0.0004215056,0.001303333,0.00034885426,0.0019162985,0.0016508711],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016287621,0.00005299928,0.00014813241,0.018066073,0.00014907387,0.00013431312,0.00005092358,0.00014253976,0.00049360713,0.0021871496,0.028185153,0.95022726],"study_design_scores_gemma":[0.00012572345,0.00021569953,0.0014342648,0.014412495,0.0003173158,0.0018318861,0.000117671625,0.00008469243,0.00024034169,0.003218671,0.97797465,0.000026642512],"about_ca_topic_score_codex":0.0010598939,"about_ca_topic_score_gemma":0.0032029916,"teacher_disagreement_score":0.0039535253,"about_ca_system_score_codex":0.00035304273,"about_ca_system_score_gemma":0.0010384514,"threshold_uncertainty_score":0.013225853},"labels":[],"label_agreement":null},{"id":"W3211652415","doi":"10.1177/17588359211056306","title":"The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Ottawa; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; William Osler Health System; McMaster University; Ottawa Hospital; University Health Network; Dalhousie University; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"AstraZeneca Canada; Pfizer","keywords":"Medicine; Lung cancer; Adjuvant; Oncology; Internal medicine; Cancer research; Pathology","score_opus":0.035450366814115994,"score_gpt":0.46102181578405454,"score_spread":0.42557144896993854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211652415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019849269,0.98662865,0.00019751556,0.008822487,0.000937343,0.000009517345,0.00010168606,0.000010952787,0.0013067892],"genre_scores_gemma":[0.020484038,0.9687816,0.00080395304,0.006174115,0.0026021327,0.000018788385,0.00016356741,0.0000075359135,0.00096429524],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964094,0.00012778236,0.00008571428,0.000040187882,0.000084535546,0.000020878964],"domain_scores_gemma":[0.9979018,0.0013607581,0.00034138354,0.000047268306,0.0002586011,0.00009013037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017935017,0.00017902079,0.0006928899,0.0009911569,0.00012684694,0.0009823926,0.0003051298,0.00089915167,0.0028230022],"category_scores_gemma":[0.0031521241,0.00012738172,0.00055773836,0.0014189923,0.00041803884,0.0021530073,0.00030128317,0.0012284325,0.00036172848],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009460133,0.00007839064,0.0012569296,0.025134422,0.00016588291,0.0002482278,0.00012516818,0.00028516946,0.0025628174,0.0065742903,0.05435927,0.9082634],"study_design_scores_gemma":[0.00067894306,0.0012524301,0.009736227,0.03216433,0.0009374097,0.0023716963,0.00039866916,0.00043100392,0.0013092364,0.011418093,0.9392556,0.00004639061],"about_ca_topic_score_codex":0.0010649211,"about_ca_topic_score_gemma":0.0030161936,"teacher_disagreement_score":0.0028230022,"about_ca_system_score_codex":0.0007755935,"about_ca_system_score_gemma":0.0014590125,"threshold_uncertainty_score":0.009485066},"labels":[],"label_agreement":null},{"id":"W4205192276","doi":"10.1177/17588359211072621","title":"Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Instituto de Salud Carlos III; Junta de Comunidades de Castilla-La Mancha","keywords":"Immunoglobulin superfamily; Carcinoembryonic antigen; Medicine; Cell adhesion molecule; Immune system; Antibody; Cancer research; Cell adhesion; Cancer; Immunology; Oncology; Cell; Bioinformatics; Internal medicine; Biology; Genetics","score_opus":0.059358061318217074,"score_gpt":0.43265147252634983,"score_spread":0.37329341120813275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205192276","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054912858,0.93921185,0.0018548842,0.0004209082,0.00028576958,0.00015804768,0.0024184745,0.00008094997,0.0006563345],"genre_scores_gemma":[0.8216114,0.17194237,0.0020548902,0.0007028374,0.0003743829,0.0004481802,0.0022739316,0.00007474644,0.0005173208],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9944846,0.0024866725,0.0010800953,0.0010841975,0.00056121236,0.00030313997],"domain_scores_gemma":[0.987944,0.008979042,0.0014562837,0.0007320954,0.00066304044,0.00022552963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007937781,0.0018588462,0.010732545,0.0034378245,0.00061801594,0.0024783458,0.0014710375,0.001635114,0.0028633634],"category_scores_gemma":[0.014063792,0.00090827193,0.03787074,0.0053632422,0.0004765211,0.00094342773,0.001125557,0.0016547454,0.0002724381],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056295665,0.000030336709,0.040678844,0.048464466,0.894417,0.00019085605,0.000044054534,0.0014681289,0.0005518386,0.00010515082,0.0006816949,0.007738027],"study_design_scores_gemma":[0.00046598635,0.00023302695,0.015938852,0.0018896986,0.9795821,0.00011058867,0.000021011583,0.00057966093,0.00015637142,0.00016988434,0.00083555473,0.000017243945],"about_ca_topic_score_codex":0.004876584,"about_ca_topic_score_gemma":0.0061529656,"teacher_disagreement_score":0.010732545,"about_ca_system_score_codex":0.0010453864,"about_ca_system_score_gemma":0.0012689179,"threshold_uncertainty_score":0.04197949},"labels":[],"label_agreement":null},{"id":"W4205632236","doi":"10.1177/17588359211059601","title":"Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline <i>BRCA1</i> / <i>2</i> mutations and hormone receptor status from the phase-3 BROCADE3 trial","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; AbbVie","keywords":"Hazard ratio; Veliparib; Breast cancer; Metastatic breast cancer; Clinical endpoint; Placebo; BRCA mutation; Germline mutation","score_opus":0.026685671906534997,"score_gpt":0.392095379246344,"score_spread":0.36540970733980904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205632236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041957,0.007325177,0.00026803417,0.0003059482,0.00008760022,0.00044522504,0.00040446062,0.000027310036,0.00071661023],"genre_scores_gemma":[0.99692696,0.0013758172,0.0002453297,0.00027705592,0.00010673362,0.0002593361,0.0005256619,0.000008520642,0.00027467633],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992956,0.00042626623,0.00006167787,0.00009676944,0.00005278416,0.00006688343],"domain_scores_gemma":[0.99929595,0.00021419265,0.00022779888,0.00006906028,0.00003744044,0.00015555393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017866053,0.000838923,0.0021538967,0.00029787325,0.00023066589,0.001003654,0.0006348145,0.0008021738,0.0016206144],"category_scores_gemma":[0.0016201477,0.00032509753,0.002499695,0.00039476485,0.00046400022,0.00048338,0.00025502127,0.0015643031,0.00024889698],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9552673,0.002228612,0.006232963,0.0005914138,0.0053643663,0.000080669335,0.00006329219,0.001099889,0.005407739,0.00006170651,0.0006522577,0.022949714],"study_design_scores_gemma":[0.87957484,0.08207787,0.026714917,0.00010351348,0.0063295537,0.0002231437,0.00006909953,0.0017614955,0.0016146757,0.0003299577,0.0011642879,0.00003673809],"about_ca_topic_score_codex":0.000496249,"about_ca_topic_score_gemma":0.0013928848,"teacher_disagreement_score":0.0021538967,"about_ca_system_score_codex":0.0005996727,"about_ca_system_score_gemma":0.00082484796,"threshold_uncertainty_score":0.009448588},"labels":[],"label_agreement":null},{"id":"W4205813526","doi":"10.1177/17588359211066677","title":"Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Calgary; Université Laval; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Toronto; Dalhousie University; University of British Columbia; BC Cancer Agency","funders":"F. Hoffmann-La Roche; AstraZeneca; Mylan; Pfizer","keywords":"Medicine; Trastuzumab; Neratinib; Oncology; Capecitabine; Internal medicine; Breast cancer; Hazard ratio; Clinical trial; Metastatic breast cancer; Cancer; Progression-free survival; Overall survival; Confidence interval; Colorectal cancer","score_opus":0.053771382150858645,"score_gpt":0.4747381370782596,"score_spread":0.420966754927401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205813526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010896066,0.97703254,0.00044622575,0.020209381,0.00035764577,0.000014224883,0.000055144184,0.000021951435,0.0007733474],"genre_scores_gemma":[0.014968885,0.96735895,0.0019171038,0.013226364,0.0017175075,0.000054740227,0.00012798015,0.000024147233,0.00060421566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622786,0.0019695582,0.0006444554,0.00033847665,0.00063766015,0.00018201637],"domain_scores_gemma":[0.981898,0.011724895,0.0027113433,0.0003950382,0.002646659,0.0006240165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014168776,0.000688975,0.0025176888,0.0025786834,0.0004301481,0.0040520183,0.0017936083,0.0026822865,0.006343753],"category_scores_gemma":[0.012340876,0.00034813565,0.0016182399,0.0034938413,0.0016057267,0.008631899,0.0011839139,0.0027783662,0.0013182886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001253961,0.00018761016,0.0022968522,0.031811018,0.00040778035,0.0002449536,0.00031341147,0.0007006039,0.0017743459,0.010604444,0.026498498,0.9239065],"study_design_scores_gemma":[0.0008238081,0.0023841234,0.0093479715,0.10770367,0.002546017,0.0021481721,0.0021741989,0.0021002595,0.001109591,0.037616733,0.831893,0.00015241852],"about_ca_topic_score_codex":0.0018466436,"about_ca_topic_score_gemma":0.004933643,"teacher_disagreement_score":0.014168776,"about_ca_system_score_codex":0.0027017079,"about_ca_system_score_gemma":0.00548165,"threshold_uncertainty_score":0.074932516},"labels":[],"label_agreement":null},{"id":"W4214529556","doi":"10.1177/17588359221081203","title":"Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Breast cancer; Covariate; Quality of life (healthcare); Repeated measures design; Cancer; Gerontology; Correlation; Analysis of variance; Demography; Physical therapy; Internal medicine; Oncology; Statistics; Mathematics","score_opus":0.014106568739178604,"score_gpt":0.31911265260787114,"score_spread":0.30500608386869255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214529556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99580836,0.0018068793,0.00010445817,0.00014026173,0.000023136734,0.00008629985,0.0013217734,0.0000074839904,0.0007013358],"genre_scores_gemma":[0.99682283,0.0002384551,0.00007951267,0.00007812012,0.000030516312,0.00013302882,0.0022771554,0.0000033503038,0.00033705996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978149,0.001094412,0.00020274533,0.000292265,0.0004304847,0.00016524771],"domain_scores_gemma":[0.99653625,0.0013796388,0.0011976883,0.0003071679,0.00024924157,0.00032994934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005221191,0.00032505568,0.0009856378,0.00037103068,0.00019042459,0.00052416575,0.00046529042,0.00035158388,0.0019561592],"category_scores_gemma":[0.0059199915,0.00018433353,0.0009307186,0.00050738454,0.00020628475,0.0003454257,0.0006324397,0.0009416896,0.00018185106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18605003,0.0013812002,0.73081493,0.0007571573,0.005699856,0.00006918067,0.00022630939,0.0019208216,0.0014082371,0.0001487719,0.003151768,0.06837175],"study_design_scores_gemma":[0.006566779,0.009062816,0.9793997,0.000047133522,0.0013587854,0.00007101106,0.000056905308,0.0013944993,0.0002872308,0.00009003018,0.0016447876,0.000020375086],"about_ca_topic_score_codex":0.0010195868,"about_ca_topic_score_gemma":0.002675851,"teacher_disagreement_score":0.005221191,"about_ca_system_score_codex":0.0004937537,"about_ca_system_score_gemma":0.00048561732,"threshold_uncertainty_score":0.027612627},"labels":[],"label_agreement":null},{"id":"W4285189908","doi":"10.1177/17588359221108685","title":"Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Calgary; Queen Elizabeth II Health Sciences Centre; McMaster University; Juravinski Cancer Centre","funders":"Pfizer Canada; Merck Canada; Ipsen; Eisai","keywords":"Medicine; Cancer therapy; Systematic review; Cancer; Kidney cancer; Oncology; MEDLINE; Intensive care medicine; Internal medicine","score_opus":0.061614521457701237,"score_gpt":0.4158854827627571,"score_spread":0.35427096130505586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285189908","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005009098,0.9989095,0.0000475155,0.00016112872,0.000041023308,0.000047563648,0.00016107294,0.00000268138,0.0001286998],"genre_scores_gemma":[0.01232151,0.9864916,0.00031609117,0.00044821686,0.00006625814,0.00013622387,0.0001720465,0.0000032445812,0.0000447916],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9943474,0.0023661826,0.001894911,0.000437387,0.00082802743,0.00012615626],"domain_scores_gemma":[0.9668105,0.023694418,0.006556394,0.00030881978,0.0023324497,0.00029735413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006732265,0.00082533504,0.007408303,0.0061506014,0.00032820262,0.0018877309,0.0014623696,0.001250671,0.003295519],"category_scores_gemma":[0.029723985,0.0007006951,0.0059354147,0.008033427,0.00057052856,0.0019219148,0.0008706735,0.0010470983,0.00022037489],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039564614,0.000019494555,0.0011218551,0.9170836,0.015353514,0.000078406774,0.00011771632,0.00014977323,0.000104954386,0.00024455116,0.0020890036,0.06324152],"study_design_scores_gemma":[0.00064326887,0.00044582243,0.0072044237,0.8546382,0.105745815,0.0006051221,0.00023524892,0.00020616222,0.00013113544,0.00040463888,0.029688573,0.00005152537],"about_ca_topic_score_codex":0.0071473387,"about_ca_topic_score_gemma":0.023274835,"teacher_disagreement_score":0.007408303,"about_ca_system_score_codex":0.0028156638,"about_ca_system_score_gemma":0.006745517,"threshold_uncertainty_score":0.03560406},"labels":[],"label_agreement":null},{"id":"W4285229704","doi":"10.1177/17588359221097940","title":"Characterizing the <i>KRAS</i> G12C mutation in metastatic colorectal cancer: a population-based cohort and assessment of expression differences in The Cancer Genome Atlas","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"KRAS; Medicine; Colorectal cancer; Population; Cancer; Oncology; Internal medicine; Mutation; Cancer research; Gene; Biology; Genetics","score_opus":0.02920145447641013,"score_gpt":0.38917827841675795,"score_spread":0.3599768239403478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285229704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718636,0.00041196783,0.00012303535,0.00003845793,0.0000031457778,0.000015338032,0.0017306483,0.00000842514,0.00048262478],"genre_scores_gemma":[0.9980292,0.0002559012,0.00010035589,0.00003455348,0.000004877766,0.00001347821,0.0014033258,0.0000066600423,0.00015154618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994862,0.000048958824,0.00004154582,0.00020077117,0.00014514115,0.00007732981],"domain_scores_gemma":[0.99916387,0.00006648766,0.00031030897,0.00009646259,0.00023942691,0.00012354579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048148562,0.00019700274,0.00040750203,0.0016500454,0.000604699,0.00074846577,0.00044857207,0.0003686462,0.0010546388],"category_scores_gemma":[0.0011654301,0.00019369386,0.0002336978,0.0021045553,0.00036372963,0.00025906312,0.0004373221,0.0003551939,0.0003294318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000465298,0.0000049304144,0.9978124,0.00001003888,0.000036504178,0.00007662693,0.00004795259,0.000019332221,0.00075334084,0.00000963329,0.00013446201,0.0010483443],"study_design_scores_gemma":[0.0000011203327,0.00001931939,0.999071,0.0000035834748,0.000017752121,0.00035413954,0.00009120583,0.000042831456,0.00009023899,0.0000089389605,0.0002971375,0.000002660139],"about_ca_topic_score_codex":0.0818069,"about_ca_topic_score_gemma":0.1151493,"teacher_disagreement_score":0.0818069,"about_ca_system_score_codex":0.00083849416,"about_ca_system_score_gemma":0.00068497774,"threshold_uncertainty_score":0.16266143},"labels":[],"label_agreement":null},{"id":"W4285270205","doi":"10.1177/17588359221094879","title":"The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Metastatic Urothelial Carcinoma; Medicine; Chemotherapy; Urothelial carcinoma; Oncology; Metastasis; Bone metastasis; Internal medicine; First line; Carcinoma; Cancer research; Cancer; Bladder cancer","score_opus":0.01586903876166198,"score_gpt":0.32684249620395206,"score_spread":0.3109734574422901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285270205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986651,0.00080171006,0.000044894517,0.00006222212,0.00000510206,0.0000047723624,0.00015355292,0.000001985675,0.000260589],"genre_scores_gemma":[0.99968743,0.00011036031,0.00003208998,0.000012943856,0.000008591619,0.0000025403344,0.00011088304,6.2741236e-7,0.00003460815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975735,0.0000633107,0.00003079502,0.00003914941,0.000059834678,0.000049570546],"domain_scores_gemma":[0.9983442,0.00039702104,0.0008637451,0.000041859177,0.000110893525,0.00024226618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044612074,0.00016186667,0.00028415926,0.00048310848,0.00030320862,0.0004881544,0.00033092508,0.00031032605,0.0012773849],"category_scores_gemma":[0.0028615121,0.00012515657,0.00035623935,0.00070965686,0.00019681516,0.00038420252,0.00029528773,0.0005025158,0.00011928423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011999928,0.000008899124,0.9985942,0.000006994041,0.000018221093,0.000089276386,0.000009993261,0.00003166389,0.00009138192,0.000004976204,0.000040086117,0.0009841671],"study_design_scores_gemma":[0.0000091992515,0.00010611641,0.9985291,0.0000072444823,0.00003237809,0.0008508907,0.000056878347,0.00018517181,0.0000711672,0.000015380847,0.00013449675,0.00000195209],"about_ca_topic_score_codex":0.0018139111,"about_ca_topic_score_gemma":0.0033613818,"teacher_disagreement_score":0.0018139111,"about_ca_system_score_codex":0.00037783346,"about_ca_system_score_gemma":0.00031980244,"threshold_uncertainty_score":0.0042732954},"labels":[],"label_agreement":null},{"id":"W4286357580","doi":"10.1177/17588359221111705","title":"Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Queen Elizabeth II Health Sciences Centre; William Osler Health System; University of Alberta; Surrey Memorial Hospital","funders":"Pfizer Canada; Amgen Canada; Thermo Scientific","keywords":"KRAS; Medicine; Colorectal cancer; Biomarker; Oncology; Guideline; Targeted therapy; Biomarker discovery; Cancer; Internal medicine; Bioinformatics; Pathology; Gene; Biology","score_opus":0.13394123132511457,"score_gpt":0.49144521244157596,"score_spread":0.3575039811164614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286357580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004522001,0.8915928,0.0046851835,0.06439462,0.0044749184,0.0013385252,0.0039928774,0.00021896738,0.0288499],"genre_scores_gemma":[0.005203848,0.928505,0.02253668,0.025526678,0.0010289925,0.0010882639,0.006933132,0.000052735304,0.0091246925],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953235,0.0009770652,0.000938277,0.00022424437,0.0022323406,0.00030465375],"domain_scores_gemma":[0.9873203,0.0019145441,0.0008559289,0.0001744314,0.009215373,0.00051945046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008160821,0.001214018,0.002374782,0.0067253713,0.0010887521,0.002093689,0.0050694677,0.0043385695,0.004900685],"category_scores_gemma":[0.012518167,0.000605556,0.003061066,0.006711469,0.0012766856,0.0016281914,0.0017089084,0.004351512,0.0030575695],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076843804,0.00006506069,0.00068990065,0.019919582,0.00018321161,0.00032942317,0.00019704948,0.00050520967,0.0006413175,0.005151129,0.5071535,0.46508783],"study_design_scores_gemma":[0.000093127266,0.000030092267,0.0020615193,0.027843472,0.00030135908,0.00059008086,0.00010381075,0.00022960104,0.00022040248,0.0024297223,0.96605164,0.000045207074],"about_ca_topic_score_codex":0.23027457,"about_ca_topic_score_gemma":0.35226312,"teacher_disagreement_score":0.76972544,"about_ca_system_score_codex":0.011927002,"about_ca_system_score_gemma":0.045474086,"threshold_uncertainty_score":0.4578684},"labels":[],"label_agreement":null},{"id":"W4288013778","doi":"10.1177/17588359221112696","title":"The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Niagara Health System; University of Toronto; Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; University of Ottawa; Jewish General Hospital; McMaster University; Juravinski Cancer Centre; McGill University; University of Calgary","funders":"Jewish General Hospital; BC Cancer Foundation; Princess Margaret Cancer Foundation; Guardant Health; Ottawa Hospital Research Institute","keywords":"Liquid biopsy; Medicine; Lung cancer; Biopsy; Circulating tumor DNA; Cell-free fetal DNA; Lung; Oncology; Pathology; Cancer research; Internal medicine; Cancer; Biology; Genetics","score_opus":0.008545333577232495,"score_gpt":0.31906501960689143,"score_spread":0.31051968602965896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288013778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9498012,0.011136651,0.014424204,0.0050498857,0.00009778681,0.0012050724,0.004948329,0.00008948384,0.013247399],"genre_scores_gemma":[0.99623483,0.00086285564,0.001998217,0.00014384974,0.000010347811,0.000058876303,0.00043608499,0.0000043573914,0.0002506225],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99682814,0.0020804678,0.0000875456,0.00016206013,0.000462542,0.00037927477],"domain_scores_gemma":[0.9900231,0.008152717,0.00076829386,0.00013148409,0.00048713022,0.00043729728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051599806,0.00082733977,0.0007052506,0.0009610224,0.00043127942,0.0016421793,0.0010033299,0.0007294008,0.0023831904],"category_scores_gemma":[0.016772045,0.0003903085,0.0016630746,0.001165691,0.000843811,0.0008573687,0.000839882,0.0011021276,0.000094461895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009482658,0.00036353632,0.05231441,0.0011755147,0.0014286113,0.00028139344,0.0000916536,0.855098,0.0009858119,0.006352,0.0026999796,0.06972642],"study_design_scores_gemma":[0.0018620994,0.0035829635,0.064699136,0.00092827994,0.0028088212,0.0004843433,0.0003263352,0.9090299,0.0013664457,0.009211031,0.005552039,0.00014851459],"about_ca_topic_score_codex":0.33115909,"about_ca_topic_score_gemma":0.2756794,"teacher_disagreement_score":0.33115909,"about_ca_system_score_codex":0.02621689,"about_ca_system_score_gemma":0.015539905,"threshold_uncertainty_score":0.65846306},"labels":[],"label_agreement":null},{"id":"W4295904913","doi":"10.1177/17588359221122714","title":"The role of gut microbiome in immune modulation in metastatic renal cell carcinoma","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Microbiome; Immunotherapy; Renal cell carcinoma; Gut microbiome; Immune system; Intensive care medicine; Gut flora; Immunology; Oncology; Bioinformatics; Biology","score_opus":0.032753435061530105,"score_gpt":0.37980260325678,"score_spread":0.3470491681952499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295904913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021749682,0.9985215,0.000104948354,0.00037410855,0.00018771387,0.000003275421,0.000018328235,0.000004959837,0.0005675165],"genre_scores_gemma":[0.0013501202,0.9978004,0.00012920082,0.00018358814,0.00013567391,0.0000046293176,0.00002293273,9.718514e-7,0.00037235607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999884,0.00003501557,0.000015505972,0.000016969314,0.000034462944,0.000014069665],"domain_scores_gemma":[0.9998522,0.00007426826,0.000022798906,0.0000037223656,0.000034799905,0.0000122685115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033576376,0.0004768937,0.0007410305,0.00096432754,0.00018473383,0.0007280497,0.00029202778,0.0006927117,0.002195582],"category_scores_gemma":[0.0006038429,0.00011489655,0.00045400963,0.0008269823,0.00021579649,0.0006603877,0.00051622355,0.00091272115,0.00070932927],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010986722,0.000051554853,0.00039038254,0.021237712,0.00016624677,0.0001780191,0.0000766156,0.0003284009,0.0023832235,0.0031479618,0.022967279,0.9489628],"study_design_scores_gemma":[0.000027485814,0.00018173209,0.0036929057,0.010689104,0.00028487833,0.0016879458,0.000119732715,0.00022725046,0.0008883396,0.0029178776,0.97925276,0.000029831528],"about_ca_topic_score_codex":0.0009132095,"about_ca_topic_score_gemma":0.001532466,"teacher_disagreement_score":0.002195582,"about_ca_system_score_codex":0.0003496297,"about_ca_system_score_gemma":0.000869357,"threshold_uncertainty_score":0.007345021},"labels":[],"label_agreement":null},{"id":"W4296502312","doi":"10.1177/17588359221126151","title":"Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Lung cancer; Internal medicine; Biopsy; Referral; Liquid biopsy; Cancer; Oncology; Clinical endpoint; Cohort study; Pathology; Clinical trial","score_opus":0.018142735730742408,"score_gpt":0.3462831243431265,"score_spread":0.3281403886123841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296502312","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6412547,0.0287048,0.2872308,0.0069087115,0.0011360636,0.0014127137,0.0044687623,0.013298552,0.015584993],"genre_scores_gemma":[0.80446124,0.0040067597,0.18105374,0.0019632534,0.0005900324,0.00050632854,0.0030180586,0.00041181987,0.0039887135],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868566,0.00042623482,0.00004487994,0.00031174492,0.0004408719,0.00009062643],"domain_scores_gemma":[0.9984888,0.00056366343,0.00030612343,0.00014385024,0.00030723016,0.00019030346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002405568,0.0005226244,0.00058981846,0.0011687881,0.00032449063,0.0015574152,0.0012475401,0.0006786107,0.0049117147],"category_scores_gemma":[0.0028355536,0.00038097816,0.00041153588,0.0005703486,0.0003793245,0.0010872337,0.0015132416,0.0009345159,0.0018465575],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004769658,0.0007593093,0.15779406,0.0010334743,0.000298968,0.00082225923,0.00027575667,0.0038780263,0.13933742,0.0016619229,0.02230358,0.6670656],"study_design_scores_gemma":[0.0023321982,0.013499016,0.34244454,0.0011329264,0.0008853119,0.023424355,0.0007722115,0.16443978,0.2998903,0.007192705,0.14351556,0.00047107655],"about_ca_topic_score_codex":0.0021584467,"about_ca_topic_score_gemma":0.0026095281,"teacher_disagreement_score":0.0049117147,"about_ca_system_score_codex":0.00085101475,"about_ca_system_score_gemma":0.001058395,"threshold_uncertainty_score":0.016431332},"labels":[],"label_agreement":null},{"id":"W4308189235","doi":"10.1177/17588359221133893","title":"Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high <i>ACE2</i> -expressing normal lung","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Canadian Institutes of Health Research; Instituto de Salud Carlos III; Israel Science Foundation; FP7 Health; Sixth Framework Programme; Canadian Cancer Society","keywords":"Medicine; Pneumonia; Lung cancer; Lung; Coronavirus disease 2019 (COVID-19); Gene; Immunology; Comorbidity; Virology; Cancer research; Pathology; Internal medicine; Biology; Genetics; Disease","score_opus":0.03554020693441197,"score_gpt":0.4457092496624502,"score_spread":0.4101690427280382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308189235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996284,0.000078157165,0.000051749754,0.00001493059,0.0000015039736,0.000002067309,0.000085959844,0.0000014489154,0.00013562955],"genre_scores_gemma":[0.99975413,0.000017558103,0.000037444894,0.000008404937,0.0000043764303,0.0000018586456,0.00014529185,9.132766e-7,0.000030020661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99973613,0.00005599337,0.000026110552,0.00009200044,0.000038899754,0.000050893887],"domain_scores_gemma":[0.99933225,0.00018923629,0.00025357318,0.00004284274,0.000047816364,0.00013427006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019366248,0.00016442453,0.00031216073,0.00039825012,0.00029492367,0.00047732212,0.0001622844,0.00027790878,0.001242228],"category_scores_gemma":[0.0009247445,0.00012764873,0.00021137929,0.00046250084,0.0002472206,0.00020889685,0.00026762005,0.0003769698,0.0001480193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004502361,0.000020406897,0.99289685,0.0000075656963,0.000023316366,0.00018221716,0.000032414544,0.000044580836,0.0053503765,0.000016545247,0.000031061118,0.000944453],"study_design_scores_gemma":[0.0000048653487,0.00008471974,0.9984864,0.0000016296613,0.00001633264,0.0005778332,0.00008947069,0.00021612104,0.000435158,0.000030608022,0.00005446088,0.000002241276],"about_ca_topic_score_codex":0.000869003,"about_ca_topic_score_gemma":0.0009792644,"teacher_disagreement_score":0.001242228,"about_ca_system_score_codex":0.00017812874,"about_ca_system_score_gemma":0.00017785364,"threshold_uncertainty_score":0.004155636},"labels":[],"label_agreement":null},{"id":"W4312211783","doi":"10.1177/17588359221143975","title":"Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"BC Cancer Foundation; Michael Smith Health Research BC","keywords":"Medicine; Liquid biopsy; Colorectal cancer; Stage (stratigraphy); Oncology; Minimal residual disease; Circulating tumor DNA; Internal medicine; Cancer; Clinical trial; Disease; Adjuvant; Leukemia","score_opus":0.06832000875268691,"score_gpt":0.42487258444342074,"score_spread":0.35655257569073384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312211783","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011910315,0.9286492,0.0024767092,0.062411394,0.0041556656,0.00002226442,0.00010575296,0.000045989655,0.00094201724],"genre_scores_gemma":[0.020033184,0.9080151,0.00957526,0.04236982,0.017732352,0.00008855245,0.00026478662,0.00007357165,0.0018474114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955776,0.0019617549,0.00089381257,0.0004165734,0.0009745077,0.0001758582],"domain_scores_gemma":[0.97029954,0.019574769,0.0020553065,0.00059323193,0.006750379,0.0007267917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0091624595,0.00059647,0.002932292,0.0016692899,0.00054776715,0.0032703234,0.0015481933,0.003498001,0.0028821894],"category_scores_gemma":[0.03724001,0.00057405065,0.0015757678,0.001444341,0.0022505599,0.0068555917,0.0010845069,0.004993686,0.0016045306],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081880944,0.00004798469,0.011840064,0.015667535,0.000508389,0.0007574009,0.0005565368,0.00025585547,0.0012021483,0.0097379405,0.097487584,0.8611198],"study_design_scores_gemma":[0.00018707594,0.000732049,0.014567566,0.039010074,0.0017719304,0.006411377,0.0027602524,0.00085780653,0.001711295,0.03260994,0.899128,0.00025267646],"about_ca_topic_score_codex":0.0036602516,"about_ca_topic_score_gemma":0.0053372304,"teacher_disagreement_score":0.0091624595,"about_ca_system_score_codex":0.0016472656,"about_ca_system_score_gemma":0.0029510749,"threshold_uncertainty_score":0.04845625},"labels":[],"label_agreement":null},{"id":"W4321795635","doi":"10.1177/17588359231152843","title":"Quality of life with ribociclib <i>versus</i> abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"National Cancer Institute; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Medicine; Breast cancer; Internal medicine; Quality of life (healthcare); Oncology; Placebo; Cancer; Hazard ratio; Clinical trial; Confidence interval; Alternative medicine; Pathology","score_opus":0.06506842105089145,"score_gpt":0.4343277424711693,"score_spread":0.36925932142027784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321795635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97261095,0.013934119,0.0014722691,0.00035896027,0.0005541122,0.002556158,0.0036954624,0.000067538815,0.0047505014],"genre_scores_gemma":[0.9926583,0.0014856964,0.0011103357,0.00024237408,0.00012093645,0.0020727746,0.0011450901,0.000010394315,0.001154168],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9949857,0.0034739687,0.0004948797,0.0003729835,0.0004059461,0.00026659918],"domain_scores_gemma":[0.99627846,0.0019338304,0.0011204615,0.0002177556,0.00018463713,0.0002648573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045586466,0.0013151298,0.003693532,0.00085824076,0.00019455659,0.0010114859,0.0010005034,0.0010341814,0.006479251],"category_scores_gemma":[0.006086348,0.00041764666,0.0071585546,0.00065101346,0.00056222366,0.0008331168,0.0010071909,0.0017348405,0.00038102176],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9408383,0.001401455,0.0043416647,0.0031627684,0.024050359,0.00003385864,0.00007764095,0.0019095574,0.00073012116,0.00045466571,0.00073802803,0.022261644],"study_design_scores_gemma":[0.571004,0.27185017,0.06043581,0.0010720233,0.072634995,0.00018748187,0.00025345298,0.011646934,0.002402539,0.002740616,0.00561789,0.00015410739],"about_ca_topic_score_codex":0.0016045795,"about_ca_topic_score_gemma":0.0021320274,"teacher_disagreement_score":0.006479251,"about_ca_system_score_codex":0.0012822383,"about_ca_system_score_gemma":0.00086349016,"threshold_uncertainty_score":0.024108768},"labels":[],"label_agreement":null},{"id":"W4323024632","doi":"10.1177/17588359231157644","title":"Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Oncology; Cancer research; Poly ADP ribose polymerase; Internal medicine; Cancer; Pharmacology; DNA; Biology; Genetics","score_opus":0.09070451031767579,"score_gpt":0.4848637584573334,"score_spread":0.39415924813965764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323024632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031623547,0.9975859,0.00021358827,0.0004139782,0.00016800716,0.000009842381,0.000027797543,0.000010535394,0.0012540739],"genre_scores_gemma":[0.0015385053,0.99699533,0.00026471217,0.00027919986,0.00011772853,0.000010243881,0.00005197452,0.0000019267038,0.00074042956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987614,0.00002594615,0.000015862182,0.000020867135,0.000046703786,0.000014437091],"domain_scores_gemma":[0.99988127,0.000049013546,0.000020606692,0.000003559113,0.000033790926,0.000011840077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003493305,0.00043207858,0.00078982156,0.0011705467,0.00019637223,0.00073011086,0.0005311491,0.0006381758,0.003054215],"category_scores_gemma":[0.00039187717,0.0001517684,0.000427413,0.00093894225,0.00022635817,0.0008472512,0.00047584748,0.0014592384,0.0013473872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000093429895,0.000090487505,0.00015313599,0.014939885,0.000076129625,0.00023242296,0.00006819603,0.00038185893,0.0028815197,0.0033150022,0.017850133,0.95991784],"study_design_scores_gemma":[0.000031451596,0.0002609948,0.0008305368,0.0035992302,0.00011789733,0.0015775708,0.000068543995,0.00016787251,0.0011613732,0.001996037,0.9901714,0.000017141472],"about_ca_topic_score_codex":0.00048236965,"about_ca_topic_score_gemma":0.0013584249,"teacher_disagreement_score":0.003054215,"about_ca_system_score_codex":0.0004004507,"about_ca_system_score_gemma":0.0005698851,"threshold_uncertainty_score":0.010217309},"labels":[],"label_agreement":null},{"id":"W4323063328","doi":"10.1177/17588359231157651","title":"Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia Hospital; University of British Columbia; Pancreas Centre (Canada)","funders":"Terry Fox Research Institute; Genome British Columbia; Pancreatic Cancer Canada Foundation; VGH and UBC Hospital Foundation","keywords":"Liquid biopsy; Medicine; Pancreatic ductal adenocarcinoma; Druggability; Pancreatic cancer; Disease; Clinical trial; Genomics; Bioinformatics; Internal medicine; Oncology; Cancer; Genome; Gene; Biology; Genetics","score_opus":0.08646251333694421,"score_gpt":0.43717743138949516,"score_spread":0.35071491805255095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323063328","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000819612,0.99772626,0.00024859168,0.0010290454,0.00027153926,0.0000030322653,0.000009283529,0.000006954056,0.00062345393],"genre_scores_gemma":[0.0007339432,0.9976404,0.00029566573,0.0006274885,0.00038277262,0.000006674243,0.00001754526,0.0000019146553,0.0002936834],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996978,0.00008161847,0.000041979383,0.000048180853,0.00010710583,0.00002329456],"domain_scores_gemma":[0.9993755,0.0003536603,0.00004985707,0.00001624387,0.0001609027,0.000043889577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012859746,0.00060329895,0.0011470824,0.0019811974,0.00023658268,0.0012691874,0.0008353892,0.0012051625,0.0013954126],"category_scores_gemma":[0.0013090195,0.0002481061,0.0004750666,0.0014315936,0.0008699894,0.0019056867,0.0008895218,0.0029961031,0.0011449194],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007459271,0.000052543073,0.0002679529,0.009402675,0.00006627792,0.00027002438,0.00009054022,0.00043184127,0.0014978903,0.012887936,0.028323963,0.9466337],"study_design_scores_gemma":[0.000015794274,0.00009006307,0.0006209148,0.0030337803,0.000058141326,0.0013334529,0.00006677338,0.00016723262,0.00047644362,0.005504154,0.98861104,0.00002215957],"about_ca_topic_score_codex":0.0009676836,"about_ca_topic_score_gemma":0.0016519986,"teacher_disagreement_score":0.0019811974,"about_ca_system_score_codex":0.0010412495,"about_ca_system_score_gemma":0.001454558,"threshold_uncertainty_score":0.007554829},"labels":[],"label_agreement":null},{"id":"W4327652478","doi":"10.1177/17588359231160141","title":"Direct GDP-KRAS <sup>G12C</sup> inhibitors and mechanisms of resistance: the tip of the iceberg","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Regeneron Pharmaceuticals; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; KRAS; Iceberg; Cancer research; Internal medicine; Pharmacology; Cancer; Physics","score_opus":0.02494405273547091,"score_gpt":0.3498188310208574,"score_spread":0.3248747782853865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327652478","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004426337,0.9810477,0.0021770678,0.008209056,0.0005437137,0.00001114943,0.000059119135,0.00007783688,0.0034480826],"genre_scores_gemma":[0.020069156,0.9711473,0.0016064583,0.0027797073,0.00066563115,0.000025196307,0.00012086166,0.000029535975,0.0035561167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997491,0.00005529073,0.000030363117,0.00003781372,0.00008208431,0.000045259814],"domain_scores_gemma":[0.9997174,0.00012475163,0.000048544036,0.000016194816,0.00006331469,0.000029777852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007707488,0.00045039586,0.0010116121,0.0007280657,0.00031154236,0.0017560859,0.0004328043,0.0010511191,0.0016603352],"category_scores_gemma":[0.00061559625,0.00028556612,0.00038105805,0.00066286325,0.0011115586,0.0023952206,0.0006078123,0.002791317,0.0014455933],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075195305,0.0001589205,0.0013846417,0.007887148,0.0001300763,0.00097474735,0.00037242024,0.00217743,0.054832913,0.06308847,0.043971952,0.82426924],"study_design_scores_gemma":[0.0000410789,0.00050802284,0.0019121136,0.00094614644,0.00008054533,0.0023971593,0.00024155411,0.00084952475,0.02121333,0.02811606,0.94363844,0.00005601989],"about_ca_topic_score_codex":0.00043325673,"about_ca_topic_score_gemma":0.0009859214,"teacher_disagreement_score":0.0017560859,"about_ca_system_score_codex":0.0010559426,"about_ca_system_score_gemma":0.00066365465,"threshold_uncertainty_score":0.007661402},"labels":[],"label_agreement":null},{"id":"W4327850169","doi":"10.1177/17588359231157633","title":"A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Western University; Centre Hospitalier de l’Université de Montréal; University of Calgary; University of Manitoba; Princess Margaret Cancer Centre; University of Toronto; University of British Columbia","funders":"Merck Canada; Eisai Canada; Eisai; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Endometrial cancer; Oncology; Internal medicine; Microsatellite instability; Lenvatinib; Metastatic breast cancer; Cancer; Breast cancer; Immunotherapy; Thyroid cancer","score_opus":0.07530303729759415,"score_gpt":0.44368306545161573,"score_spread":0.3683800281540216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327850169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000578829,0.9944988,0.000074281685,0.004112256,0.00017950602,0.000011241467,0.000064777596,0.0000031951402,0.00047714222],"genre_scores_gemma":[0.0067296023,0.98806095,0.0003787183,0.0038294764,0.00071937265,0.000031959982,0.000096241674,0.0000035782782,0.00015000637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983358,0.0007724533,0.00040791137,0.00012982955,0.0003084186,0.000045477078],"domain_scores_gemma":[0.9891206,0.0076710726,0.0018768901,0.00011302586,0.0010497649,0.00016862147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00512169,0.0003244804,0.002019626,0.0018793403,0.00022906248,0.0016757828,0.00059804344,0.0014754082,0.003093735],"category_scores_gemma":[0.009961796,0.00021551829,0.0012546966,0.0035682519,0.0005637866,0.00273955,0.00064642413,0.0015389968,0.00042078333],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073935965,0.00005439235,0.0018033397,0.15371488,0.0007210315,0.00039358012,0.0002054671,0.0005570818,0.0012796529,0.00449347,0.027063409,0.8089743],"study_design_scores_gemma":[0.0009204584,0.0016282374,0.011283324,0.25411844,0.0040349187,0.004720486,0.0012699182,0.00061268604,0.00086806127,0.01063714,0.70980346,0.000102764294],"about_ca_topic_score_codex":0.0009944671,"about_ca_topic_score_gemma":0.003569807,"teacher_disagreement_score":0.00512169,"about_ca_system_score_codex":0.0009967131,"about_ca_system_score_gemma":0.002235127,"threshold_uncertainty_score":0.027086437},"labels":[],"label_agreement":null},{"id":"W4361799923","doi":"10.1177/17588359231162577","title":"Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université de Sherbrooke","funders":"","keywords":"Microsatellite instability; Medicine; DNA mismatch repair; Colorectal cancer; Immune checkpoint; Oncology; Chemotherapy; Adjuvant; Cancer; Immune system; Cancer research; Immunotherapy; Internal medicine; Immunology; Biology; Gene; Genetics","score_opus":0.0512075099216513,"score_gpt":0.41381590591825096,"score_spread":0.36260839599659966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361799923","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007320507,0.9991503,0.00003561625,0.00046411762,0.000074251446,0.0000017511613,0.0000067880537,0.0000017518879,0.00019219288],"genre_scores_gemma":[0.0007868809,0.99845076,0.00010033473,0.00036946477,0.00019509249,0.000004922233,0.000016341966,9.372859e-7,0.00007527792],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99961156,0.00012330164,0.00009493527,0.00005399899,0.000092795555,0.000023315797],"domain_scores_gemma":[0.9986784,0.00089654693,0.00019911022,0.00002142499,0.00016611566,0.000038481845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013798159,0.00050108857,0.0015368228,0.0013370971,0.00020808616,0.0010055485,0.00092798605,0.001053657,0.0016852677],"category_scores_gemma":[0.002811284,0.00020769329,0.00087106024,0.0012366234,0.00058420066,0.0012589266,0.00056881114,0.00183736,0.0005633176],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011440114,0.00003495829,0.00041821145,0.034806598,0.00021909023,0.0001697844,0.00007506038,0.00043564232,0.00036154134,0.0028289345,0.017399523,0.9431362],"study_design_scores_gemma":[0.00006992918,0.00024908243,0.0031823847,0.056448493,0.0009414348,0.0028937997,0.00021391861,0.000303324,0.0004970015,0.0046577877,0.93050027,0.00004243863],"about_ca_topic_score_codex":0.0009846677,"about_ca_topic_score_gemma":0.0022794877,"teacher_disagreement_score":0.0016852677,"about_ca_system_score_codex":0.00067777536,"about_ca_system_score_gemma":0.0014924052,"threshold_uncertainty_score":0.0072972775},"labels":[],"label_agreement":null},{"id":"W4361802115","doi":"10.1177/17588359231152845","title":"Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University Health Centre; Juravinski Cancer Centre; St. Michael's Hospital; University of British Columbia; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Sanofi","keywords":"Medicine; Prostate cancer; Hormonal therapy; Oncology; Hormone therapy; Cancer; Prostate; Internal medicine; Intensive care medicine; Breast cancer","score_opus":0.21126107155521642,"score_gpt":0.5522541500154357,"score_spread":0.3409930784602192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361802115","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050949963,0.99841666,0.000094983436,0.00028471003,0.00009487877,0.000084978084,0.00013941691,0.000003780968,0.000371097],"genre_scores_gemma":[0.003583806,0.9957141,0.00017891514,0.00015671876,0.000055161032,0.00012811767,0.000121378405,0.0000017969538,0.000059998485],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.994499,0.0017471876,0.0020601947,0.00035071102,0.0011399077,0.00020297877],"domain_scores_gemma":[0.963197,0.029157257,0.004820947,0.00036960753,0.0022175964,0.00023768682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008392417,0.0010131878,0.0041505713,0.010756431,0.00076354033,0.0026220407,0.0015317671,0.0023414432,0.003371177],"category_scores_gemma":[0.038905494,0.0007168257,0.004424192,0.0147085115,0.000863055,0.001995894,0.0014936826,0.0012830488,0.0002739932],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010141926,0.00003627828,0.0011833514,0.7842144,0.0021272171,0.00012960048,0.0006277356,0.00023976229,0.00011662959,0.00065300695,0.004417752,0.20615287],"study_design_scores_gemma":[0.000026151552,0.0000752516,0.0032892476,0.9554738,0.007186954,0.00029172064,0.00036741953,0.000092078226,0.00007493914,0.000290028,0.032811876,0.00002063942],"about_ca_topic_score_codex":0.0133788,"about_ca_topic_score_gemma":0.01826654,"teacher_disagreement_score":0.0133788,"about_ca_system_score_codex":0.0028985003,"about_ca_system_score_gemma":0.011522348,"threshold_uncertainty_score":0.044383883},"labels":[],"label_agreement":null},{"id":"W4361988864","doi":"10.1177/17588359231156382","title":"A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"FP7 Health; Pharmacyclics; Sanofi Genzyme; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Servier; AstraZeneca; Institut National Du Cancer; Canadian Cancer Society; Foundation Medicine; Fondation ARC pour la Recherche sur le Cancer; Seagen; Puma Biotechnology; Actuate Therapeutics; Symphogen; Pfizer; Incyte; Grifols; EQRx; BeiGene; European Commission; Sanofi; Halozyme; Chugai Pharmaceutical; Israel Science Foundation; Ipsen; Array BioPharma; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Instituto de Salud Carlos III; Amgen; Novartis Pharmaceuticals Corporation; Les Laboratories Pierre Fabre","keywords":"Medicine; Oncology; Clinical trial; Internal medicine; Immunotherapy; Metastasis; Cancer","score_opus":0.17780642204238725,"score_gpt":0.5108081939300281,"score_spread":0.3330017718876408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361988864","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018280828,0.0020012595,0.9645148,0.005104438,0.00030509714,0.0006100325,0.0021189202,0.001608153,0.0054564034],"genre_scores_gemma":[0.18757373,0.0046296692,0.7972434,0.0023464405,0.000326741,0.0022543839,0.002073346,0.00025287212,0.0032994635],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99864286,0.00080824934,0.000068128145,0.00022199424,0.00019908888,0.000059740738],"domain_scores_gemma":[0.99667263,0.0023278927,0.00034320087,0.0003627666,0.00018039386,0.00011303002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045899185,0.0008649275,0.0011924072,0.001139376,0.0003943861,0.0022894724,0.0010659756,0.0013332341,0.0060387664],"category_scores_gemma":[0.0069534327,0.00079823384,0.0014571921,0.0009148369,0.001189902,0.0019531427,0.0010068964,0.001867158,0.0013597317],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012244802,0.0005827324,0.013977078,0.0021122003,0.0006701905,0.00039953596,0.00033217628,0.3974912,0.15993412,0.194812,0.0119685065,0.21649578],"study_design_scores_gemma":[0.0002617976,0.00089741853,0.003920533,0.00026904154,0.00036834038,0.000314031,0.00016925957,0.60694915,0.021024711,0.30368766,0.062020328,0.00011779847],"about_ca_topic_score_codex":0.0010973546,"about_ca_topic_score_gemma":0.0015112696,"teacher_disagreement_score":0.0060387664,"about_ca_system_score_codex":0.0018059615,"about_ca_system_score_gemma":0.0023281001,"threshold_uncertainty_score":0.02427411},"labels":[],"label_agreement":null},{"id":"W4378530850","doi":"10.1177/17588359231177008","title":"Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Cochrane Library; Internal medicine; Oncology; Lung cancer; Biomarker; MEDLINE; Sample size determination; Systematic review; Cancer; Adjuvant therapy; Prospective cohort study; Pathological","score_opus":0.021904039043796487,"score_gpt":0.3505206216591146,"score_spread":0.32861658261531806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378530850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037397528,0.9946878,0.00035036416,0.00019547493,0.00009568518,0.00018406619,0.0005458197,0.00001699112,0.00018411184],"genre_scores_gemma":[0.13862868,0.85606617,0.0018117923,0.00090791483,0.00025369308,0.0010072927,0.0010427184,0.000025583637,0.0002562565],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99273986,0.0029128795,0.0023875292,0.00083660986,0.0008516623,0.00027140757],"domain_scores_gemma":[0.97915924,0.0155905625,0.0028390181,0.0005448316,0.001626047,0.00024023042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010044973,0.0023266121,0.01601754,0.0071793557,0.0006448572,0.002848394,0.0021536169,0.0022123926,0.0029204118],"category_scores_gemma":[0.028378973,0.0012786083,0.03324801,0.008478735,0.0006136821,0.0015805516,0.0012898835,0.0015665091,0.00028054457],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011617376,0.000030992152,0.0077856854,0.52856976,0.44926795,0.00016008328,0.00009361864,0.00057165604,0.00022158759,0.00012338912,0.0006890831,0.011324515],"study_design_scores_gemma":[0.00027871964,0.00014866662,0.005471605,0.034258705,0.9576605,0.000119251425,0.00004684342,0.0002076985,0.00009518666,0.00015196938,0.0015338399,0.000027040245],"about_ca_topic_score_codex":0.007153408,"about_ca_topic_score_gemma":0.015955737,"teacher_disagreement_score":0.01601754,"about_ca_system_score_codex":0.002205838,"about_ca_system_score_gemma":0.00423167,"threshold_uncertainty_score":0.053123534},"labels":[],"label_agreement":null},{"id":"W4379383902","doi":"10.1177/17588359231175440","title":"Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Ottawa Hospital; Sinai Health System; University of Toronto; University of Alberta; University of Calgary","funders":"National Cancer Institute; Mylan; AstraZeneca Canada; Seagen; Gilead Sciences; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Clinical trial; Biomarker; Disease; Hormone receptor; Pertuzumab; Cancer; Population; Human Epidermal Growth Factor Receptor 2","score_opus":0.13996570816914805,"score_gpt":0.5367814479793399,"score_spread":0.39681573981019186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379383902","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007934044,0.9985709,0.00007308522,0.0007483986,0.00010294624,0.0000032904081,0.0000083360965,0.0000036965885,0.00040989253],"genre_scores_gemma":[0.0005527016,0.9985531,0.00013019612,0.00045493033,0.00012788175,0.0000049054916,0.000012988253,0.0000012367473,0.0001621278],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997204,0.00009167896,0.000041144653,0.000041285955,0.00007972099,0.000025751177],"domain_scores_gemma":[0.9993255,0.00041999,0.00006687,0.000013756044,0.00013710644,0.000036830148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001705392,0.0005937441,0.0017626692,0.001528291,0.00021235539,0.0013434163,0.0010343317,0.00112377,0.0023730814],"category_scores_gemma":[0.0012561932,0.00021026045,0.00060368725,0.001461899,0.0005734015,0.0017778947,0.0006777017,0.0030594263,0.0012275225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012825192,0.00007214268,0.00012709074,0.01661779,0.00011543747,0.00014463798,0.00006019813,0.00040800517,0.00081138697,0.007723448,0.019536987,0.9542545],"study_design_scores_gemma":[0.000078102494,0.00026729386,0.0005799297,0.011058766,0.00021365042,0.0010673972,0.0001049815,0.00021759456,0.00030807088,0.004879908,0.98120236,0.00002186737],"about_ca_topic_score_codex":0.0008113477,"about_ca_topic_score_gemma":0.0025364899,"teacher_disagreement_score":0.0023730814,"about_ca_system_score_codex":0.0007323913,"about_ca_system_score_gemma":0.0012678113,"threshold_uncertainty_score":0.009019077},"labels":[],"label_agreement":null},{"id":"W4379508645","doi":"10.1177/17588359231178125","title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2− early breast cancer","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Genentech; PharmaMar; Novartis Institutes for BioMedical Research; Daewoong Pharmaceutical Company; Astellas Pharma; Eisai; Seagen; Mersana Therapeutics; Mylan; Syndax Pharmaceuticals; Clovis Oncology; Astex Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; F. Hoffmann-La Roche; Amgen; Radius Health; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Exelixis; Sanofi; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Anastrozole; Palbociclib; Metastatic breast cancer; Goserelin; Randomization; Cancer; Adjuvant therapy; Clinical trial; Tamoxifen; Gynecology","score_opus":0.0373529934834873,"score_gpt":0.3836976276393478,"score_spread":0.3463446341558605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379508645","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010512107,0.006296942,0.022179995,0.011122646,0.006684751,0.92505056,0.004355012,0.0003483212,0.013449722],"genre_scores_gemma":[0.028361665,0.0013559035,0.028126927,0.010131783,0.0013306241,0.92707455,0.0010076708,0.000045185956,0.0025656621],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9546955,0.033588436,0.0029745507,0.0039948244,0.003463443,0.0012832424],"domain_scores_gemma":[0.9860729,0.0040327995,0.0022903134,0.0017658332,0.002588658,0.003249435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05800121,0.0033571448,0.0038947838,0.0018537554,0.0025831526,0.0032672521,0.003411683,0.0058220048,0.01785388],"category_scores_gemma":[0.04148613,0.0022366352,0.0023287914,0.0018506673,0.0048344294,0.0026361183,0.0016718227,0.007815777,0.007986967],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4644683,0.012175169,0.013180738,0.023527764,0.0038823525,0.0018967082,0.0016695043,0.0060554743,0.009857903,0.102802224,0.14727181,0.21321201],"study_design_scores_gemma":[0.52255005,0.043921094,0.012986856,0.010387782,0.0031324292,0.0010438927,0.00045483804,0.0105837295,0.0035949338,0.048693523,0.34217465,0.00047622249],"about_ca_topic_score_codex":0.00087896315,"about_ca_topic_score_gemma":0.0025988594,"teacher_disagreement_score":0.05800121,"about_ca_system_score_codex":0.002501612,"about_ca_system_score_gemma":0.010033382,"threshold_uncertainty_score":0.30674338},"labels":[],"label_agreement":null},{"id":"W4381889685","doi":"10.1177/17588359231183682","title":"Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa; Dr. H. Bliss Murphy Cancer Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Université Laval; Moncton Hospital; Université de Sherbrooke; Queen's University; Pancreas Centre (Canada)","funders":"BC Cancer Foundation","keywords":"Medicine; Colorectal cancer; Circulating tumor DNA; Disease; Oncology; Cancer; Internal medicine; Cancer research","score_opus":0.01740138278459184,"score_gpt":0.34738841161848244,"score_spread":0.3299870288338906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381889685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99321294,0.0010565598,0.0049479324,0.00007269897,0.000006748528,0.00009759856,0.0002033956,0.00006399095,0.00033816783],"genre_scores_gemma":[0.9890322,0.00027822074,0.010073576,0.000063942876,0.0000056328386,0.00007156182,0.00030546458,0.000009455367,0.00015996996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991617,0.0003309979,0.00004801684,0.00018472101,0.00021144624,0.000063130734],"domain_scores_gemma":[0.9980457,0.0010293326,0.0004057777,0.00012667075,0.00025794026,0.00013447778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002551615,0.00039998753,0.0005996267,0.0005082878,0.00022268583,0.0005553823,0.00037445276,0.00035539642,0.0005404683],"category_scores_gemma":[0.0049432456,0.0002522026,0.00027309085,0.00037213945,0.0003247577,0.00040280362,0.00034725145,0.00045501045,0.00015300028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006917423,0.0006977261,0.4950945,0.0004885584,0.0004386126,0.00016961584,0.0002932922,0.04353508,0.34260312,0.00021003089,0.00066778046,0.108884305],"study_design_scores_gemma":[0.000864689,0.015744478,0.5050062,0.00013119764,0.0008757047,0.0015815371,0.0002728015,0.14116774,0.32883763,0.0011471151,0.0042567393,0.0001142563],"about_ca_topic_score_codex":0.0018937376,"about_ca_topic_score_gemma":0.005668126,"teacher_disagreement_score":0.002551615,"about_ca_system_score_codex":0.00066829147,"about_ca_system_score_gemma":0.00057340314,"threshold_uncertainty_score":0.013494372},"labels":[],"label_agreement":null},{"id":"W4383647203","doi":"10.1177/17588359231183668","title":"Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; London Health Sciences Centre","funders":"","keywords":"SABR volatility model; Medicine; Lung cancer; Oncology; Clinical trial; Radiation therapy; Narrative review; Internal medicine; Medical physics; Intensive care medicine","score_opus":0.14720216806980715,"score_gpt":0.5244359166054591,"score_spread":0.37723374853565195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383647203","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036823327,0.9993825,0.00003668641,0.00020631457,0.00009254992,0.0000042134147,0.000008836958,0.0000020044672,0.00023009095],"genre_scores_gemma":[0.00021033183,0.99929786,0.00010674113,0.00017046515,0.000085862775,0.000005687311,0.0000115390185,5.705828e-7,0.00011088752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975413,0.00006218658,0.000051497143,0.00003643335,0.00007941688,0.000016372898],"domain_scores_gemma":[0.99944645,0.000346024,0.00008020199,0.000010724349,0.00009283837,0.000023798479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009977097,0.0007875748,0.0016111034,0.0026115333,0.00025597177,0.000998576,0.0009382984,0.0010662484,0.0031512356],"category_scores_gemma":[0.0011978602,0.00030664098,0.0008314117,0.002501724,0.0004069748,0.0013975152,0.0006423273,0.0017762681,0.001111512],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012088073,0.000078114084,0.00011727273,0.05407672,0.00022509633,0.00016351824,0.000076945,0.00034558002,0.0008909031,0.0035428319,0.026214845,0.9141473],"study_design_scores_gemma":[0.000060302504,0.00023949066,0.0008804607,0.027700886,0.00048875064,0.0011354497,0.000106214065,0.00013736147,0.00026233337,0.0026462597,0.966314,0.000028493496],"about_ca_topic_score_codex":0.0009857715,"about_ca_topic_score_gemma":0.0026962392,"teacher_disagreement_score":0.0031512356,"about_ca_system_score_codex":0.000562019,"about_ca_system_score_gemma":0.0014893579,"threshold_uncertainty_score":0.010541916},"labels":[],"label_agreement":null},{"id":"W4383647369","doi":"10.1177/17588359231183676","title":"Clinical trial reform in the post-COVID era","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical trial; Medicine; Telehealth; Pandemic; Health care; Telemedicine; Coronavirus disease 2019 (COVID-19); Pathology; Political science; Disease","score_opus":0.24283984504246986,"score_gpt":0.5987535896468035,"score_spread":0.3559137446043336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383647369","genre_codex":"commentary","genre_gemma":"review","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010443734,0.16577642,0.018222189,0.7603042,0.014448884,0.0069761137,0.00062679406,0.00033090482,0.022870788],"genre_scores_gemma":[0.19428065,0.0747912,0.07387414,0.589122,0.030303165,0.03062117,0.0009065224,0.00039007526,0.005711049],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.29309377,0.6322193,0.029155508,0.014848778,0.023005623,0.0076770657],"domain_scores_gemma":[0.12222004,0.74938744,0.036689486,0.033556707,0.041343544,0.016802792],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.65912825,0.0010472658,0.004458077,0.005292099,0.005346846,0.025688872,0.011652144,0.020122906,0.009748994],"category_scores_gemma":[0.7381485,0.0018674406,0.00430095,0.009453451,0.024877742,0.025379525,0.018014293,0.022073513,0.0018774726],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004060115,0.0006784043,0.0040081646,0.041136943,0.0027176496,0.0005771589,0.014199374,0.0035774463,0.00064139254,0.29085198,0.10424715,0.5333042],"study_design_scores_gemma":[0.008233426,0.0038146698,0.011538959,0.056901272,0.0013467515,0.00048581505,0.0055134934,0.0021619769,0.0009246339,0.20782065,0.70099455,0.00026384753],"about_ca_topic_score_codex":0.004155727,"about_ca_topic_score_gemma":0.0054254895,"teacher_disagreement_score":0.34087175,"about_ca_system_score_codex":0.027404685,"about_ca_system_score_gemma":0.119192176,"threshold_uncertainty_score":0.42035562},"labels":[],"label_agreement":null},{"id":"W4386137644","doi":"10.1177/17588359231192399","title":"The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Durvalumab; Atezolizumab; Chemoimmunotherapy; Oncology; Radiation therapy; Immunotherapy; Lung cancer; Internal medicine; Chemotherapy; Prophylactic cranial irradiation; Pembrolizumab; Clinical trial; Cancer","score_opus":0.05325617056729078,"score_gpt":0.5120078415180879,"score_spread":0.4587516709507971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386137644","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0758444,0.8608251,0.0027403636,0.040305905,0.0028710535,0.00019020204,0.0002508128,0.000060609702,0.016911687],"genre_scores_gemma":[0.5506503,0.41185105,0.005236108,0.01658924,0.011444769,0.00030791954,0.00062262063,0.000047463942,0.0032504075],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9980166,0.0012441552,0.00017734614,0.00019646685,0.00023730335,0.00012800054],"domain_scores_gemma":[0.9917319,0.0043221163,0.0014665311,0.0004410827,0.0010512447,0.00098712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006105164,0.0003002463,0.00082133966,0.00052882504,0.00041118098,0.0022452306,0.00082004344,0.0009872589,0.004727014],"category_scores_gemma":[0.015652008,0.00015948951,0.0007314654,0.0007521162,0.0010100987,0.002427771,0.0011502962,0.0024694048,0.0006454828],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032523293,0.00047037812,0.01948558,0.0038148272,0.00028717352,0.00046535957,0.00031707433,0.0013292327,0.0013795033,0.004374443,0.017406093,0.94741803],"study_design_scores_gemma":[0.0032368477,0.018239189,0.1874208,0.023271168,0.0033585553,0.008124856,0.0031048602,0.0073399823,0.0046960544,0.04246626,0.69837517,0.00036630325],"about_ca_topic_score_codex":0.0013425549,"about_ca_topic_score_gemma":0.0036799896,"teacher_disagreement_score":0.006105164,"about_ca_system_score_codex":0.0010431121,"about_ca_system_score_gemma":0.0026490476,"threshold_uncertainty_score":0.032287598},"labels":[],"label_agreement":null},{"id":"W4387133870","doi":"10.1177/17588359231198943","title":"Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sarcoma; Proportional hazards model; Radiation therapy; Internal medicine; Soft tissue sarcoma; Osteosarcoma; Angiosarcoma; Oncology; Bone Sarcoma; Chemotherapy; Retrospective cohort study; Multivariate analysis; Database; Surgery; Pathology","score_opus":0.041873041809638155,"score_gpt":0.41402758277280705,"score_spread":0.3721545409631689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387133870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957948,0.0002939183,0.00006764396,0.000047654015,0.0000043763594,0.00007469524,0.0027300038,0.000005538603,0.0009814334],"genre_scores_gemma":[0.99504197,0.0002328338,0.00010196833,0.00005429522,0.000013446061,0.000049978713,0.0042832983,0.0000041909047,0.00021803255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922657,0.000061594605,0.00006953062,0.0001911251,0.0002338569,0.00021733803],"domain_scores_gemma":[0.9983424,0.00013849878,0.0004625683,0.0001274145,0.0004670685,0.00046190794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000718712,0.00043749934,0.00040544756,0.0020420048,0.0011651592,0.00061642966,0.0007100482,0.00046485203,0.0021239463],"category_scores_gemma":[0.0015663772,0.00035093355,0.00049995905,0.003508403,0.00058654224,0.00037358812,0.00078300136,0.0003945489,0.00037388757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010478998,0.000026391106,0.9980963,0.000019800776,0.000032569995,0.00009041053,0.00013608493,0.00004291493,0.00010587556,0.000018240564,0.00038708342,0.0009396229],"study_design_scores_gemma":[0.000020173737,0.000097468124,0.9982522,0.0000122810925,0.00003782222,0.00029387808,0.0003780803,0.00009969153,0.00003719198,0.000011148584,0.0007527082,0.000007367106],"about_ca_topic_score_codex":0.45382488,"about_ca_topic_score_gemma":0.60057837,"teacher_disagreement_score":0.5461751,"about_ca_system_score_codex":0.004848593,"about_ca_system_score_gemma":0.00546389,"threshold_uncertainty_score":0.90236664},"labels":[],"label_agreement":null},{"id":"W4391325299","doi":"10.1177/17588359231220511","title":"The role of aberrant DNA methylation in cancer initiation and clinical impacts","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Health and Medical Research Council; National Cancer Institute; National Institutes of Health; Sierra Oncology; Swiss Cancer Research Foundation; Eisai; BeiGene; Clovis Oncology; AstraZeneca","keywords":"DNA methylation; Epigenetics; Methylation; Cancer research; DNA repair; Biology; Cancer epigenetics; MSH2; Context (archaeology); MLH1; DNA mismatch repair; Medicine; Genetics; Gene; Gene expression","score_opus":0.022225462354696527,"score_gpt":0.42088266976538263,"score_spread":0.3986572074106861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391325299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017271884,0.9659602,0.0046881125,0.004040467,0.00046659776,0.000020081166,0.00025586959,0.0000552803,0.0072416095],"genre_scores_gemma":[0.13857041,0.85385865,0.0027546848,0.00087483146,0.0007082919,0.000033583627,0.00018665179,0.000016349084,0.002996595],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964535,0.00010458383,0.00003738038,0.00007650874,0.00009164427,0.000044526485],"domain_scores_gemma":[0.9995728,0.00023572013,0.00007455951,0.000018364686,0.000068284055,0.000030192496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007478601,0.0002577109,0.0005832827,0.0007739065,0.00027837022,0.001004589,0.0003125562,0.0007118213,0.0013946964],"category_scores_gemma":[0.0011606074,0.00016743531,0.000303677,0.0006704118,0.00080668565,0.000714189,0.00057132955,0.0011222926,0.000457571],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053009135,0.00007315013,0.02119835,0.009212147,0.00026735268,0.0029305767,0.001162107,0.0030181597,0.100318834,0.04766342,0.011079491,0.8025464],"study_design_scores_gemma":[0.00002704059,0.00060240045,0.06745246,0.0032994216,0.00037857937,0.015085981,0.00082880555,0.0015797572,0.061884284,0.044854455,0.8038666,0.00014018998],"about_ca_topic_score_codex":0.0010353285,"about_ca_topic_score_gemma":0.0010738509,"teacher_disagreement_score":0.0013946964,"about_ca_system_score_codex":0.00081635645,"about_ca_system_score_gemma":0.0008041629,"threshold_uncertainty_score":0.005923152},"labels":[],"label_agreement":null},{"id":"W4394850223","doi":"10.1177/17588359241247008","title":"Real-world experience supporting the role of oncologic resection and adjuvant chemotherapy in biliary tract cancers","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Hazard ratio; Gallbladder cancer; Internal medicine; Cohort; Capecitabine; Cancer; Confidence interval; Population; Surgery; Intrahepatic Cholangiocarcinoma; Chemotherapy; Retrospective cohort study; Oncology; Gastroenterology; Colorectal cancer","score_opus":0.023284938017677767,"score_gpt":0.3965308868266167,"score_spread":0.3732459488089389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394850223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99124885,0.006437546,0.00024089398,0.00067721884,0.00001349282,0.000021786018,0.00016094647,0.000004238212,0.001195062],"genre_scores_gemma":[0.99729866,0.0021898656,0.00019079255,0.000099452416,0.000017966162,0.000009676842,0.00015062361,0.0000020603695,0.000040875177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729496,0.001655741,0.00029313355,0.00014736195,0.0004261402,0.00018262277],"domain_scores_gemma":[0.98477846,0.0068421634,0.004986194,0.0005905368,0.0017996286,0.0010029088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045800493,0.00009566865,0.00018574536,0.00041213952,0.0002986114,0.0007078524,0.0003092678,0.00024896156,0.0005803439],"category_scores_gemma":[0.018058341,0.00013321165,0.00023113504,0.00085808465,0.0006076866,0.00037421635,0.0005941845,0.00041241423,0.000082690756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061733264,0.00008405168,0.9627536,0.00024809886,0.00008483807,0.0006485952,0.0009653944,0.00043220673,0.0003262242,0.00012156933,0.00082583306,0.03289206],"study_design_scores_gemma":[0.00006420867,0.0007815632,0.98439085,0.00025540526,0.00010807746,0.0038215374,0.0018462723,0.00088219385,0.00048898254,0.00009292041,0.007248346,0.00001958123],"about_ca_topic_score_codex":0.010943246,"about_ca_topic_score_gemma":0.018046169,"teacher_disagreement_score":0.010943246,"about_ca_system_score_codex":0.0019435219,"about_ca_system_score_gemma":0.001387148,"threshold_uncertainty_score":0.024221897},"labels":[],"label_agreement":null},{"id":"W4396863343","doi":"10.1177/17588359241250158","title":"Clinical activity of pembrolizumab in refractory <i>MDM2</i> -amplified advanced intimal sarcomas","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Deciphera Pharmaceuticals; Iterion Therapeutics; Karyopharm Therapeutics; Amgen; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb; Symphogen; GlaxoSmithKline","keywords":"Pembrolizumab; Medicine; Sarcoma; Tumor microenvironment; Refractory (planetary science); Oncology; Soft tissue sarcoma; Internal medicine; Immunotherapy; Chemotherapy; Pathology; Cancer research; Cancer","score_opus":0.04223307785315796,"score_gpt":0.44233554916761947,"score_spread":0.4001024713144615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396863343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931524,0.0037816807,0.00036019587,0.0002116053,0.000020909245,0.00007808808,0.00005436189,0.000016827637,0.002323815],"genre_scores_gemma":[0.99876523,0.0005720771,0.00017287389,0.00013986781,0.000018882496,0.000014290142,0.00009514445,0.0000016510456,0.00021994772],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99990344,0.000024714927,0.000012406002,0.000016759854,0.000016478316,0.000026196614],"domain_scores_gemma":[0.999808,0.00007166282,0.000027078957,0.000012082265,0.000011104029,0.000070136266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036290634,0.00022239114,0.0004340047,0.00020192891,0.00023737396,0.0002693212,0.0001361813,0.000346551,0.00041830313],"category_scores_gemma":[0.00059101847,0.00007689756,0.00023174167,0.00009904557,0.00019321925,0.00019933304,0.00012816282,0.0005563616,0.00011523526],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022037255,0.0027727482,0.21444158,0.0010293082,0.0006911532,0.083863065,0.0015089468,0.0051586903,0.2539853,0.001004994,0.0027168528,0.4107901],"study_design_scores_gemma":[0.0041804905,0.06739825,0.6505708,0.00040079292,0.0009813651,0.16678205,0.00075383106,0.01662093,0.0593236,0.0018051858,0.03108395,0.000098713215],"about_ca_topic_score_codex":0.00034898848,"about_ca_topic_score_gemma":0.0007775045,"teacher_disagreement_score":0.0004340047,"about_ca_system_score_codex":0.00030901196,"about_ca_system_score_gemma":0.00015292647,"threshold_uncertainty_score":0.0022420287},"labels":[],"label_agreement":null},{"id":"W4399614669","doi":"10.1177/17588359241255174","title":"PARP inhibitors in non-ovarian gynecologic cancers","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ovarian cancer; Context (archaeology); Olaparib; Oncology; PARP inhibitor; Endometrial cancer; Internal medicine; Poly ADP ribose polymerase; Cancer research; Cancer; Polymerase; Biology; Gene","score_opus":0.021426977265556247,"score_gpt":0.39641454717827285,"score_spread":0.3749875699127166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399614669","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036184906,0.98421407,0.0005260594,0.0024061592,0.00031919562,0.000018126157,0.00010288635,0.000027490874,0.008767591],"genre_scores_gemma":[0.035141744,0.9579617,0.0010247751,0.0013785906,0.0003854772,0.000024469578,0.0002031762,0.0000070140486,0.0038731508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998994,0.00002761525,0.000015024622,0.000012353436,0.000032433752,0.00001320715],"domain_scores_gemma":[0.99987316,0.000050752875,0.000034336466,0.000004345209,0.00002420265,0.0000131626175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023653511,0.00017274146,0.00029231163,0.00036921087,0.00015291625,0.00043701997,0.00022555458,0.0003353586,0.0023437433],"category_scores_gemma":[0.00043272492,0.00007776269,0.0002793787,0.00041496378,0.00014002662,0.00027715228,0.00026145717,0.000744974,0.00060721126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033148975,0.00008481869,0.0011925178,0.004668208,0.00011938969,0.00091433333,0.00009139715,0.00085367996,0.006682628,0.0060994867,0.044505905,0.93445635],"study_design_scores_gemma":[0.000111440524,0.00050197716,0.004308824,0.0018200825,0.00016413332,0.004992382,0.000087210625,0.00042125097,0.004482763,0.0039105895,0.97918254,0.00001693886],"about_ca_topic_score_codex":0.0006221315,"about_ca_topic_score_gemma":0.00200285,"teacher_disagreement_score":0.0023437433,"about_ca_system_score_codex":0.00035663234,"about_ca_system_score_gemma":0.00044251618,"threshold_uncertainty_score":0.007840633},"labels":[],"label_agreement":null},{"id":"W4401261376","doi":"10.1177/17588359241266179","title":"Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada","year":2024,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; University of Ottawa; Université Laval; Centre hospitalier universitaire de Québec; St. Michael's Hospital; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Mount Sinai Hospital; Vancouver General Hospital; University of Calgary; University of Alberta; Ottawa Hospital; University Health Network; University of Toronto; University of British Columbia; Baker Hughes (Canada)","funders":"","keywords":"GiST; Medicine; Imatinib mesylate; Family medicine; Imatinib; Pathology; Internal medicine; Stromal cell","score_opus":0.06216501679158278,"score_gpt":0.4649279505218246,"score_spread":0.40276293373024186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401261376","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0073749735,0.13132164,0.026514482,0.6673768,0.019442543,0.004911246,0.016323758,0.0013828333,0.12535174],"genre_scores_gemma":[0.20139864,0.20146844,0.25126287,0.22570832,0.0046115266,0.006535413,0.033264983,0.0010563775,0.07469347],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9574354,0.009870078,0.008325953,0.0024245991,0.0163113,0.005632695],"domain_scores_gemma":[0.7928321,0.008485861,0.005951206,0.0016751974,0.17397283,0.017082823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029285006,0.0015192739,0.001705509,0.010353982,0.008928945,0.008235038,0.010012374,0.0058481726,0.011824654],"category_scores_gemma":[0.07972252,0.0009970441,0.0033778867,0.010621974,0.0044010365,0.0035118419,0.006228023,0.005734117,0.0029609716],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084888336,0.000068522255,0.009525025,0.0060644057,0.00015615276,0.00093106757,0.004261161,0.0016842012,0.0007622491,0.013845171,0.8156489,0.14696832],"study_design_scores_gemma":[0.00010140381,0.00005659074,0.017320823,0.017635208,0.00022626434,0.0008650633,0.0071406537,0.0009054104,0.0004994718,0.004584563,0.95042664,0.00023804244],"about_ca_topic_score_codex":0.94599694,"about_ca_topic_score_gemma":0.96380323,"teacher_disagreement_score":0.86829686,"about_ca_system_score_codex":0.13170312,"about_ca_system_score_gemma":0.48019752,"threshold_uncertainty_score":0.9555775},"labels":[],"label_agreement":null},{"id":"W4402335895","doi":"10.1177/17588359241271913","title":"HER2 becomes a novel survival biomarker for gastric cancer patients: a pooled analysis","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Science Foundation of Hubei Province","keywords":"Medicine; Biomarker; Cancer; Oncology; Internal medicine; Trastuzumab; Breast cancer","score_opus":0.031961686564817036,"score_gpt":0.39643225979441893,"score_spread":0.3644705732296019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402335895","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031629592,0.96234,0.0021180634,0.0003453587,0.00032711908,0.00051186694,0.0020313668,0.00006213439,0.0006344669],"genre_scores_gemma":[0.69113034,0.29506615,0.0048287516,0.0012332808,0.0007210315,0.0024131732,0.003528053,0.000086526,0.0009927112],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9881143,0.0066113686,0.0025926218,0.0013646055,0.0009675049,0.00034961398],"domain_scores_gemma":[0.9844738,0.010102775,0.0028301484,0.0009469586,0.0013575732,0.00028877065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018390613,0.0028649794,0.016401747,0.0064554377,0.0004496861,0.003628373,0.0016259104,0.0021769158,0.0034610017],"category_scores_gemma":[0.027496018,0.001207624,0.050264124,0.006410251,0.00053719955,0.0020168244,0.0019008204,0.0015220925,0.0003878131],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006142465,0.000030075998,0.00971647,0.07617323,0.8995725,0.0000962824,0.00004670553,0.0006418059,0.00025113998,0.000078275545,0.00043731037,0.006813681],"study_design_scores_gemma":[0.0007750992,0.00024774476,0.005639596,0.0026576342,0.9894035,0.000057211884,0.00002635284,0.0002763355,0.0000739736,0.000149528,0.00067207083,0.000020860713],"about_ca_topic_score_codex":0.0031951517,"about_ca_topic_score_gemma":0.0058941077,"teacher_disagreement_score":0.018390613,"about_ca_system_score_codex":0.0015719389,"about_ca_system_score_gemma":0.0019210213,"threshold_uncertainty_score":0.09726},"labels":[],"label_agreement":null},{"id":"W4402938149","doi":"10.1177/17588359241277656","title":"Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McGill University Health Centre","funders":"Eisai; Clovis Oncology; Incyte; Novocure; Regeneron Pharmaceuticals; Seagen; Gilead Sciences; Genentech; Mersana Therapeutics; AstraZeneca; Pfizer","keywords":"Medicine; Placebo; Adverse effect; Common Terminology Criteria for Adverse Events; Internal medicine; Endometrial cancer; Randomized controlled trial; Population; Carboplatin; Phases of clinical research; Chemotherapy; Oncology; Surgery; Cancer; Pathology","score_opus":0.01383054762002973,"score_gpt":0.35803513108909374,"score_spread":0.344204583469064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402938149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98001957,0.011039848,0.0007834628,0.0006513154,0.00041204834,0.0048478544,0.00067929615,0.00012315148,0.0014434609],"genre_scores_gemma":[0.98553526,0.0042453283,0.0018502846,0.0009949788,0.00044818458,0.004741709,0.00083114405,0.000023192124,0.001329854],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99891293,0.0007108841,0.0000683765,0.00015696874,0.00008113547,0.00006977446],"domain_scores_gemma":[0.99916923,0.00017511097,0.00033351246,0.00006298652,0.000058687834,0.00020040874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025849373,0.000982387,0.0029685856,0.0003501444,0.00035825814,0.00090060587,0.0007390322,0.0012507817,0.0036000246],"category_scores_gemma":[0.0018311954,0.0005338361,0.0017384571,0.00038104155,0.0010098591,0.0006804856,0.0003509605,0.002168449,0.00052227185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9667973,0.0051144026,0.0010515527,0.0011127676,0.0015678313,0.000038846145,0.000050892242,0.0003216553,0.004169432,0.000070778,0.000638073,0.019066395],"study_design_scores_gemma":[0.9162266,0.08058577,0.0015707678,0.000031294203,0.00048512724,0.00003774748,0.000010571464,0.00023054608,0.00028357707,0.000052236883,0.0004783917,0.0000073274873],"about_ca_topic_score_codex":0.00036487344,"about_ca_topic_score_gemma":0.001108018,"teacher_disagreement_score":0.0036000246,"about_ca_system_score_codex":0.0005471248,"about_ca_system_score_gemma":0.0012445,"threshold_uncertainty_score":0.013670623},"labels":[],"label_agreement":null},{"id":"W4403509921","doi":"10.1177/17588359241289200","title":"Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Canadian Institutes of Health Research; Fondation ARC pour la Recherche sur le Cancer; FP7 Capacities; Pfizer; European Commission; Novartis Pharmaceuticals Corporation; Canadian Cancer Society; Eli Lilly and Company","keywords":"Medicine; Identification (biology); Transcriptome; Gene; Key (lock); Computational biology; Correlation; Oncology; Internal medicine; Cancer research; Bioinformatics; Gene expression; Biology; Genetics","score_opus":0.008267509903340301,"score_gpt":0.28174128653232877,"score_spread":0.2734737766289885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403509921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976306,0.0002302069,0.0013690653,0.00004034383,0.0000026428108,0.000015723837,0.00049783476,0.000019252977,0.00019437216],"genre_scores_gemma":[0.99847823,0.00005631054,0.0008264454,0.000012479458,0.0000045280653,0.000013171283,0.0005378231,0.0000038101014,0.000067116845],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9998777,0.000024652687,0.000007763173,0.00004110892,0.000022619062,0.000026088239],"domain_scores_gemma":[0.99935037,0.0001710356,0.0002772147,0.000039397204,0.00007488942,0.000087083274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003383971,0.00019872558,0.00036763353,0.0007108939,0.00021854171,0.00033265597,0.00014906346,0.00017099829,0.0012354578],"category_scores_gemma":[0.0009160309,0.00009918432,0.00021162452,0.0007888696,0.00022465122,0.00020012946,0.00029150536,0.0002594183,0.0001783359],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024234115,0.00010902471,0.91548705,0.00011620394,0.00018752692,0.00048714294,0.000105188956,0.0030493785,0.060917377,0.00017663493,0.0005956201,0.01634539],"study_design_scores_gemma":[0.0000465578,0.00026174396,0.9816159,0.000011372892,0.00014213126,0.00057575706,0.00015309658,0.008379538,0.0076832436,0.0005747907,0.00054457004,0.000011303646],"about_ca_topic_score_codex":0.00059683487,"about_ca_topic_score_gemma":0.001100505,"teacher_disagreement_score":0.0012354578,"about_ca_system_score_codex":0.00031917257,"about_ca_system_score_gemma":0.00033784978,"threshold_uncertainty_score":0.004132986},"labels":[],"label_agreement":null},{"id":"W4405764199","doi":"10.1177/17588359241308466","title":"Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Oncology; Internal medicine; Epidermal growth factor receptor; Lung cancer; Cancer research; ROS1; Crizotinib; Stage (stratigraphy); Targeted therapy; Cancer; Adenocarcinoma; Biology","score_opus":0.015666433802951872,"score_gpt":0.41040352604992875,"score_spread":0.3947370922469769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405764199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99971074,0.00005622959,0.000049958435,0.000003825435,7.749049e-7,0.0000021163426,0.00010704544,0.0000011715575,0.0000680443],"genre_scores_gemma":[0.9996215,0.000019654899,0.000027825272,0.000002790349,0.0000017817252,0.000002081745,0.00029899785,6.8394985e-7,0.00002449014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998324,0.00003982504,0.000022067536,0.000045385696,0.00003087173,0.000029437457],"domain_scores_gemma":[0.9990876,0.0002131681,0.000376275,0.000059461985,0.00010383991,0.00015976092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046532616,0.00020190695,0.0002282123,0.0004625381,0.00015524033,0.00027542244,0.00021206564,0.0001749891,0.00067464914],"category_scores_gemma":[0.0010277922,0.00009198942,0.00029558263,0.00030309937,0.00019217472,0.00018614606,0.00029867401,0.00021698987,0.00014327886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054884725,0.00002342769,0.99626166,0.000009863817,0.000051536867,0.0001903867,0.000022626029,0.00017197116,0.0011302097,0.0000096441645,0.000032843567,0.0015468035],"study_design_scores_gemma":[0.000014039693,0.00047875146,0.9976388,0.0000040776367,0.00005344779,0.0007127918,0.00006716141,0.00040001163,0.0004964684,0.00002817914,0.00010323319,0.0000029717055],"about_ca_topic_score_codex":0.00072650344,"about_ca_topic_score_gemma":0.001164449,"teacher_disagreement_score":0.00072650344,"about_ca_system_score_codex":0.00026358338,"about_ca_system_score_gemma":0.0002367973,"threshold_uncertainty_score":0.0024609566},"labels":[],"label_agreement":null},{"id":"W4406124968","doi":"10.1177/17588359241308784","title":"The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; William Osler Health System; Queen Elizabeth II Health Sciences Centre; University of Ottawa; Dalhousie University; University of Toronto; University of Manitoba; Juravinski Cancer Centre; University of British Columbia; University Health Network; Ottawa Hospital; CancerCare Manitoba; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Eli Lilly Canada; Bayer Canada; Pfizer Canada; Novartis Pharmaceuticals Canada; Bristol-Myers Squibb Canada; EMD Serono; Astellas Pharma; Genentech; AstraZeneca Canada; Amgen Canada; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Epidermal growth factor receptor; KRAS; Anaplastic lymphoma kinase; Medicine; Crizotinib; Cancer research; Lung cancer; ROS1; Erlotinib; Clinical trial; Biomarker; EGFR inhibitors; Cancer; Targeted therapy; Oncology; Internal medicine; Biology; Adenocarcinoma; Colorectal cancer","score_opus":0.022030025022744974,"score_gpt":0.4331020654722201,"score_spread":0.4110720404494751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406124968","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019556743,0.9933809,0.00068067544,0.002532319,0.00013362363,0.00003219138,0.00015355964,0.000016532867,0.0011144498],"genre_scores_gemma":[0.008757355,0.986555,0.002103319,0.0014968242,0.0004947681,0.000072116374,0.00021727888,0.000009337275,0.00029399485],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741143,0.0011980057,0.00056429266,0.00019217409,0.0005567529,0.000077310346],"domain_scores_gemma":[0.9903026,0.007430528,0.00093263265,0.00017574576,0.0010138188,0.00014463966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057980195,0.0003863867,0.002073192,0.0026559415,0.00020621513,0.0019261634,0.0006387554,0.00076632673,0.0022755382],"category_scores_gemma":[0.0072055534,0.00017452719,0.0008534555,0.002981383,0.0005205984,0.0027386034,0.0005864411,0.0012153607,0.000614426],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033801378,0.00010255392,0.00096012454,0.038840033,0.00027987408,0.00028970238,0.0001387012,0.00074110465,0.0038239046,0.0047664815,0.0069517903,0.9427677],"study_design_scores_gemma":[0.00021548633,0.0023680562,0.008555431,0.04689615,0.0014448476,0.002365719,0.0006432077,0.0009890577,0.0035145106,0.0144494455,0.91847515,0.00008287844],"about_ca_topic_score_codex":0.0003095312,"about_ca_topic_score_gemma":0.0010966021,"teacher_disagreement_score":0.0057980195,"about_ca_system_score_codex":0.0009124533,"about_ca_system_score_gemma":0.0021654014,"threshold_uncertainty_score":0.030663252},"labels":[],"label_agreement":null},{"id":"W4407230737","doi":"10.1177/17588359251316176","title":"TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Astellas Pharma; Daiichi-Sankyo; Natera; Puma Biotechnology; Syndax Pharmaceuticals; Chugai Pharmaceutical; Nihon Medi-Physics; Eisai; Jazz Pharmaceuticals; Incyte; Taiho Pharmaceutical; Spectrum Pharmaceuticals; Boston Scientific Corporation; Gilead Sciences; Exelixis; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Pembrolizumab; Internal medicine; Breast cancer; Chemotherapy; Clinical endpoint; Oncology; Adjuvant; Triple-negative breast cancer; Cancer; Clinical trial; Immunotherapy","score_opus":0.01792386089167593,"score_gpt":0.41262272750791656,"score_spread":0.39469886661624065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407230737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98050135,0.0022071819,0.00086140836,0.0007501349,0.00054243597,0.0106489,0.0020681184,0.00016887598,0.0022515005],"genre_scores_gemma":[0.96203494,0.0031118705,0.0039121467,0.0020719746,0.00072097307,0.017754855,0.0031144433,0.00006685443,0.0072119487],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990232,0.0005882219,0.000039102983,0.00012361773,0.000062452906,0.00016350923],"domain_scores_gemma":[0.99853957,0.00029620808,0.00033033467,0.00012095309,0.000083032144,0.0006298178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032059574,0.0027150668,0.002935334,0.0006019558,0.0005003187,0.0012169239,0.0015349106,0.0018941965,0.008653352],"category_scores_gemma":[0.0019848591,0.0009459492,0.0018089957,0.000597922,0.0017542295,0.0013826657,0.0005527668,0.0034959237,0.0014400271],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9586334,0.023194656,0.0007720438,0.00037235353,0.000396912,0.00003002264,0.000051222414,0.000404527,0.0035515586,0.00012330923,0.0008793705,0.011590712],"study_design_scores_gemma":[0.85796285,0.13939649,0.0009706487,0.000015726586,0.00020429977,0.00002913325,0.000020164565,0.00027846335,0.00043864868,0.000082409824,0.00058977003,0.000011327111],"about_ca_topic_score_codex":0.0013166824,"about_ca_topic_score_gemma":0.0029353525,"teacher_disagreement_score":0.008653352,"about_ca_system_score_codex":0.0013272017,"about_ca_system_score_gemma":0.0023144996,"threshold_uncertainty_score":0.028948307},"labels":[],"label_agreement":null},{"id":"W4408459343","doi":"10.1177/17588359251323985","title":"Immunotherapy in advanced, <i>KRAS</i> G12C-mutant non-small-cell lung cancer: current strategies and future directions","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"KRAS; Medicine; Cancer research; Blockade; Lung cancer; Cancer; Mutation; Immunotherapy; Mutant; Selumetinib; Oncology; Internal medicine; Biology; Colorectal cancer; Receptor","score_opus":0.016739884954371346,"score_gpt":0.4375702361328022,"score_spread":0.4208303511784309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408459343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017101728,0.9982413,0.00012327162,0.00025310292,0.00016660414,0.0000071556556,0.000023084447,0.000009178157,0.0010052524],"genre_scores_gemma":[0.00060158514,0.99825794,0.00016299708,0.00019982613,0.00010546851,0.00000908349,0.000033654636,0.0000015197476,0.0006279542],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99991286,0.000016541198,0.0000114193335,0.000014769586,0.000032116357,0.000012309151],"domain_scores_gemma":[0.9998884,0.000048925864,0.00001816502,0.0000031446305,0.000030017678,0.000011299847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033354387,0.00056186743,0.0009233139,0.001185442,0.00016154196,0.00068648934,0.00051163766,0.0006345934,0.0040762057],"category_scores_gemma":[0.00032588944,0.00015255886,0.00044032012,0.0010482186,0.00020919662,0.00085308676,0.00048316628,0.0013516028,0.001766167],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077336255,0.000084280946,0.00007908602,0.014111684,0.00006856156,0.00008851413,0.000041461968,0.0003099714,0.0020911503,0.002071293,0.023338102,0.9576386],"study_design_scores_gemma":[0.000035016823,0.0001751282,0.0005545906,0.003958958,0.00011850332,0.0007499461,0.000043788692,0.00012688743,0.00046764853,0.0015027822,0.9922537,0.000013104237],"about_ca_topic_score_codex":0.0004629523,"about_ca_topic_score_gemma":0.0011799892,"teacher_disagreement_score":0.0040762057,"about_ca_system_score_codex":0.00032076918,"about_ca_system_score_gemma":0.00055631285,"threshold_uncertainty_score":0.013636291},"labels":[],"label_agreement":null},{"id":"W4408682588","doi":"10.1177/17588359251326710","title":"Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Novartis Pharmaceuticals Canada; Genentech; Astellas Pharma; Seagen; University of Toronto; Genomic Health; F. Hoffmann-La Roche; Purdue University; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Novartis; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Adverse effect; Discontinuation; Breast cancer; Adjuvant; Oncology; Clinical trial; Disease; Internal medicine; Cancer; Intensive care medicine; Quality of life (healthcare); Metastatic breast cancer","score_opus":0.05930661329680937,"score_gpt":0.42576301221026475,"score_spread":0.3664563989134554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408682588","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017008294,0.15318918,0.02079436,0.5048536,0.0598279,0.0012841546,0.005551086,0.005610583,0.24718827],"genre_scores_gemma":[0.016408479,0.21778534,0.05009248,0.41138244,0.07699011,0.0023874969,0.00504687,0.0013302161,0.2185766],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981845,0.00059047673,0.00033017498,0.00017354092,0.00057523575,0.00014600347],"domain_scores_gemma":[0.98866946,0.0042808703,0.00067629875,0.00027529403,0.0047646677,0.0013334261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025412648,0.0011583815,0.0014962765,0.0029263324,0.0009700236,0.00244828,0.0018181967,0.006900106,0.09485975],"category_scores_gemma":[0.027526315,0.00059766084,0.0014795491,0.0019290908,0.0006797532,0.0035760726,0.001898854,0.005998311,0.07635389],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024603389,0.00002881243,0.00016724337,0.00028289834,0.000005299485,0.0003831194,0.0000522649,0.000066906374,0.00010411131,0.00024867506,0.91877663,0.079859376],"study_design_scores_gemma":[0.00006457307,0.000048516642,0.0007126834,0.0020629812,0.000015976952,0.0037847157,0.00019148781,0.00017607588,0.00009976343,0.002286526,0.99051964,0.000036929552],"about_ca_topic_score_codex":0.0027422626,"about_ca_topic_score_gemma":0.007822144,"teacher_disagreement_score":0.09485975,"about_ca_system_score_codex":0.001135729,"about_ca_system_score_gemma":0.003121915,"threshold_uncertainty_score":0.31733745},"labels":[],"label_agreement":null},{"id":"W4409528322","doi":"10.1177/17588359251327992","title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Chugai Pharmaceutical; Samsung; Aptitude Health; Astellas Pharma; Eisai; Relay Therapeutics; Seagen; Silverback Therapeutics; Daewoong Pharmaceutical Company; AstraZeneca España; Puma Biotechnology; Genentech; Veracyte; Mersana Therapeutics; Menarini Silicon Biosystems; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; HCA Healthcare; Les Laboratories Pierre Fabre; G1 Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Durvalumab; Gemcitabine; Clinical endpoint; Internal medicine; Oncology; Carboplatin; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Cisplatin","score_opus":0.031952928587810535,"score_gpt":0.43753937024167455,"score_spread":0.40558644165386404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409528322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98633844,0.001975231,0.00062456616,0.0008303358,0.0005906888,0.005968989,0.0014489007,0.00012469091,0.0020982358],"genre_scores_gemma":[0.97835714,0.002138917,0.0021738042,0.0020075203,0.000572711,0.0076914662,0.002015121,0.000039325547,0.0050039757],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99926585,0.00038219214,0.000030170648,0.000112520946,0.00004952799,0.00015975744],"domain_scores_gemma":[0.9986972,0.00025571007,0.00025382175,0.00008439728,0.00006237206,0.00064650085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024283782,0.0022357726,0.0028928844,0.0004834323,0.00049514906,0.0013355954,0.0014305551,0.0018483417,0.0068590306],"category_scores_gemma":[0.0016073541,0.00093423814,0.00170538,0.00046658202,0.0015617656,0.0012707714,0.00050723803,0.0036401127,0.0014835474],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9613875,0.021625068,0.00067595846,0.00026697156,0.00041288702,0.000033745488,0.000051522213,0.0003909007,0.0036360004,0.00012087628,0.00079558394,0.010602876],"study_design_scores_gemma":[0.87358546,0.12359892,0.001022499,0.000013964654,0.00022659793,0.000031482945,0.000022688388,0.00039224644,0.00045290092,0.000097000295,0.0005443131,0.000011916724],"about_ca_topic_score_codex":0.0013314392,"about_ca_topic_score_gemma":0.0032278248,"teacher_disagreement_score":0.0068590306,"about_ca_system_score_codex":0.0012582624,"about_ca_system_score_gemma":0.0019769159,"threshold_uncertainty_score":0.022945762},"labels":[],"label_agreement":null},{"id":"W4410212347","doi":"10.1177/17588359251332154","title":"Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agricultural Research Institute of Ontario; McMaster University; University of Alberta; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"Debiopharm","keywords":"Avelumab; Medicine; Lung cancer; Tolerability; Internal medicine; Oncology; Adverse effect; Cancer; Response Evaluation Criteria in Solid Tumors; Nivolumab; Toxicity; Phases of clinical research; Immunotherapy","score_opus":0.029801408251035926,"score_gpt":0.418773363259961,"score_spread":0.38897195500892506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410212347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996696,0.0007221597,0.0003442858,0.00008073313,0.000037501846,0.0014023765,0.00024137078,0.000025848462,0.00044976213],"genre_scores_gemma":[0.9942926,0.0006081603,0.0012101178,0.00018259046,0.00014343286,0.0018603441,0.0006322063,0.000017433465,0.0010531166],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9983406,0.00096212805,0.000105113926,0.000232347,0.00016385737,0.00019596596],"domain_scores_gemma":[0.9978593,0.0005416811,0.0004990809,0.00032971695,0.00012162958,0.00064855156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042815167,0.001319587,0.0023623663,0.00078025187,0.00044439203,0.0012080243,0.0013342452,0.0012630238,0.0021880881],"category_scores_gemma":[0.0017738094,0.00071808114,0.0016385823,0.0007165075,0.0015226854,0.0015343736,0.0005693801,0.0031919882,0.0006658682],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73349863,0.14479066,0.0064439126,0.0005903217,0.001028349,0.00016217321,0.00032300752,0.0027110525,0.05859023,0.00018078864,0.000721577,0.050959215],"study_design_scores_gemma":[0.19411682,0.7918686,0.007350971,0.000014300748,0.00025732454,0.00012663403,0.000037035705,0.0005937983,0.0047950167,0.00009320646,0.00072533794,0.000021053622],"about_ca_topic_score_codex":0.0004698887,"about_ca_topic_score_gemma":0.0010293542,"teacher_disagreement_score":0.0042815167,"about_ca_system_score_codex":0.0011852386,"about_ca_system_score_gemma":0.0013368992,"threshold_uncertainty_score":0.02264309},"labels":[],"label_agreement":null},{"id":"W4410743176","doi":"10.1177/17588359251339919","title":"Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sinai Health System; CancerCare Manitoba; Mount Sinai Hospital; University of British Columbia; University of Toronto; Women's College Hospital; University of Manitoba; BC Cancer Agency","funders":"Eisai Canada","keywords":"Medicine; Breast cancer; Diagnosis code; Cancer; Demography; Internal medicine; Gynecology; Population","score_opus":0.09776540213586021,"score_gpt":0.49013002552391066,"score_spread":0.39236462338805045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410743176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749068,0.0005519788,0.0002139329,0.0011362655,0.0000204311,0.000050683182,0.02033226,0.000033308366,0.0027544082],"genre_scores_gemma":[0.9909958,0.00027417642,0.00021349949,0.00019423394,0.000017676477,0.00004565913,0.0069380538,0.000006158019,0.0013145986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987503,0.00008468832,0.000095673306,0.00017519553,0.0005540931,0.00033990375],"domain_scores_gemma":[0.9967583,0.00015398597,0.0016978977,0.00008523057,0.00078744214,0.0005171855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081952004,0.00019310747,0.00020387745,0.0009813701,0.00075720745,0.0007611731,0.00063340936,0.0003160046,0.0014416855],"category_scores_gemma":[0.0039229128,0.00021946695,0.0005444662,0.0018359753,0.0003702122,0.00042214757,0.00066576607,0.00045900588,0.0001428625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006800939,0.000019268038,0.9934058,0.000038552786,0.000053825413,0.00005102439,0.00034639283,0.00024939582,0.00015018112,0.00012888768,0.0023235246,0.0031650465],"study_design_scores_gemma":[0.0000025562815,0.000011472082,0.9985116,0.000010636881,0.000007559558,0.000020669451,0.00014198179,0.00021449226,0.000033255936,0.0000071864574,0.0010354081,0.000003173411],"about_ca_topic_score_codex":0.937582,"about_ca_topic_score_gemma":0.9543862,"teacher_disagreement_score":0.062417984,"about_ca_system_score_codex":0.019722367,"about_ca_system_score_gemma":0.011943416,"threshold_uncertainty_score":0.14309645},"labels":[],"label_agreement":null},{"id":"W4411680582","doi":"10.1177/17588359251351449","title":"Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Radioactivity and Radon Measurements","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"H2020 Euratom","keywords":"Radon; Lung cancer; Medicine; Radon exposure; Environmental health; Oncology","score_opus":0.06435925687664187,"score_gpt":0.45725076388737323,"score_spread":0.3928915070107314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411680582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99016386,0.0047029927,0.00033767382,0.000041952964,0.000009512358,0.000028008653,0.003952921,0.000008406643,0.00075457856],"genre_scores_gemma":[0.9950277,0.001215769,0.00031721767,0.00003672271,0.000013586483,0.00004161395,0.0032114414,0.000004557765,0.00013141656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990145,0.00027028905,0.0003285409,0.00020725242,0.00012810018,0.00005124493],"domain_scores_gemma":[0.9976908,0.0006631383,0.0011551135,0.00015514107,0.00022937902,0.00010638384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017001178,0.00018449566,0.0005328887,0.0021329536,0.0001456141,0.0006499949,0.0002671459,0.00038813383,0.00091471215],"category_scores_gemma":[0.0031572026,0.00021358412,0.000901296,0.0029777086,0.00015288449,0.00048234093,0.00047373326,0.0001931546,0.00014959714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028426433,0.000013155734,0.9955064,0.00029425044,0.0006434233,0.00011142019,0.000089789166,0.00008261123,0.00033969947,0.00002863642,0.00016059661,0.0024457243],"study_design_scores_gemma":[0.000023175558,0.0001041401,0.9974119,0.00007382209,0.00047317948,0.00054378493,0.0001457731,0.000051059633,0.00017607184,0.00002051354,0.00097094936,0.0000056410245],"about_ca_topic_score_codex":0.0014778164,"about_ca_topic_score_gemma":0.0016213391,"teacher_disagreement_score":0.0021329536,"about_ca_system_score_codex":0.00013728917,"about_ca_system_score_gemma":0.0002030398,"threshold_uncertainty_score":0.008991182},"labels":[],"label_agreement":null},{"id":"W4412634163","doi":"10.1177/17588359251357719","title":"Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Dalhousie University; University of Calgary; Spinal Cord Injury BC; University of British Columbia; Princess Margaret Cancer Centre; BC Cancer Agency; Nova Scotia Health Authority; BC Cancer Foundation; Juravinski Cancer Centre","funders":"Eisai Canada; AstraZeneca Canada","keywords":"Medicine; Atezolizumab; Bevacizumab; Lenvatinib; Clinical endpoint; Oncology; Durvalumab; Internal medicine; Hepatocellular carcinoma; Embolization; Perioperative; Sorafenib; Clinical trial; Nivolumab; Surgery; Immunotherapy; Cancer; Chemotherapy","score_opus":0.041585286424058614,"score_gpt":0.3582130287363358,"score_spread":0.3166277423122772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412634163","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063082944,0.99155957,0.00013319698,0.000509443,0.00010577324,0.000018828096,0.00003118551,0.000007768981,0.0013258778],"genre_scores_gemma":[0.14798835,0.8478884,0.0011611395,0.0013640535,0.0005652896,0.00010703398,0.00020286953,0.000011709424,0.00071115734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991917,0.0004151091,0.00017308496,0.00007526162,0.00011046022,0.00003439536],"domain_scores_gemma":[0.99849117,0.001030901,0.00028572796,0.000025951635,0.00011293503,0.000053279062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018714694,0.00024691556,0.0013282602,0.0006411585,0.00013792767,0.00073010876,0.00034936296,0.00033213245,0.0013447714],"category_scores_gemma":[0.0031194761,0.00012324558,0.001167192,0.0004408018,0.00018855189,0.00067009754,0.00027632777,0.0008119058,0.00017322127],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003723162,0.00014197563,0.002224022,0.017685346,0.001585903,0.00019789362,0.00006790001,0.00057625,0.002024506,0.00085344154,0.004028799,0.96689075],"study_design_scores_gemma":[0.008203615,0.028493915,0.059293002,0.051357348,0.029027376,0.009786457,0.0006796449,0.0029238397,0.012228715,0.0062067304,0.7916383,0.00016099041],"about_ca_topic_score_codex":0.00029650953,"about_ca_topic_score_gemma":0.0010122644,"teacher_disagreement_score":0.0018714694,"about_ca_system_score_codex":0.00048453515,"about_ca_system_score_gemma":0.0005820142,"threshold_uncertainty_score":0.009897351},"labels":[],"label_agreement":null},{"id":"W4413427043","doi":"10.1177/17588359251361883","title":"The role of immunotherapy in resectable non-small-cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Immunotherapy; Lung cancer; Oncology; Cancer; Internal medicine","score_opus":0.01845210998458962,"score_gpt":0.4051781740363202,"score_spread":0.3867260640517306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413427043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008994169,0.9988869,0.000054169483,0.0002777407,0.00011961849,0.0000037112254,0.000009708108,0.0000029705918,0.0005553314],"genre_scores_gemma":[0.0007124583,0.9986351,0.000089811554,0.00021831483,0.00011276544,0.0000055371593,0.0000146329485,8.020912e-7,0.00021047115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997464,0.00006900199,0.000039857674,0.000035429057,0.00008472825,0.000024659656],"domain_scores_gemma":[0.99952996,0.000295892,0.000050308234,0.000010520548,0.0000906242,0.00002263495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085533323,0.00048614788,0.0010028009,0.0014227607,0.00021287233,0.00097693,0.00052692165,0.0008739696,0.0025216627],"category_scores_gemma":[0.0012501314,0.00016303151,0.00061810104,0.0012155223,0.00035573388,0.0011076909,0.0005660512,0.0015096817,0.0010345116],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075760676,0.000046198686,0.00019483252,0.02391635,0.00011059261,0.00011108519,0.000060634433,0.00029584122,0.0010899225,0.0038578531,0.018444404,0.9517965],"study_design_scores_gemma":[0.00002675423,0.00016600067,0.0010110628,0.009276446,0.00017459031,0.0009256628,0.000059102553,0.00011576056,0.00048374987,0.002533001,0.9852123,0.000015619316],"about_ca_topic_score_codex":0.0007156961,"about_ca_topic_score_gemma":0.0014674838,"teacher_disagreement_score":0.0025216627,"about_ca_system_score_codex":0.00048114263,"about_ca_system_score_gemma":0.0012788477,"threshold_uncertainty_score":0.008435786},"labels":[],"label_agreement":null},{"id":"W4414977427","doi":"10.1177/17588359251342241","title":"A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McGill University Health Centre","funders":"Daiichi Sankyo Europe; Genentech; Eisai; Natera; Seagen; Ipsen; Clovis Oncology; NRG Oncology; Incyte; Loxo Oncology; Toray Industries; Novocure; Regeneron Pharmaceuticals; Karyopharm Therapeutics; Mersana Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; PharmaMar; Celgene; Pfizer","keywords":"Placebo; Endometrial cancer; Plain language; Biomarker; English language; MEDLINE","score_opus":0.03257147208396524,"score_gpt":0.3963698474130543,"score_spread":0.3637983753290891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414977427","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046041046,0.9436427,0.00042731277,0.0110792015,0.022898091,0.00061553053,0.011697322,0.00013724339,0.009042185],"genre_scores_gemma":[0.002619531,0.96909595,0.00058327854,0.007497156,0.006870883,0.0005020853,0.006166093,0.000051170817,0.006613902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802846,0.00040693168,0.000756232,0.0001221225,0.00059455086,0.00009178497],"domain_scores_gemma":[0.98907906,0.0051373085,0.0027217392,0.00015958167,0.002677378,0.00022497239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025455095,0.001067014,0.003464444,0.004886588,0.00032014408,0.0024992097,0.0013310849,0.0015971557,0.03703128],"category_scores_gemma":[0.012438478,0.00048619867,0.002384178,0.005449045,0.0004356337,0.0016193427,0.00082995766,0.0014560533,0.0067544105],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006241832,0.000036412952,0.00021940144,0.26794684,0.0006245211,0.00012626708,0.0000772314,0.00012781582,0.00052702386,0.001039492,0.48600435,0.24264656],"study_design_scores_gemma":[0.00037410896,0.0003794989,0.0022693507,0.123166256,0.0017386472,0.00056721433,0.000075010474,0.00007481158,0.00044675363,0.0006787838,0.8701834,0.000046067846],"about_ca_topic_score_codex":0.0025498536,"about_ca_topic_score_gemma":0.0023477818,"teacher_disagreement_score":0.03703128,"about_ca_system_score_codex":0.0011920076,"about_ca_system_score_gemma":0.0042638103,"threshold_uncertainty_score":0.123881996},"labels":[],"label_agreement":null},{"id":"W4415229284","doi":"10.1177/17588359251385393","title":"Orthopedic interventions and outcomes in patients with metastatic renal cell carcinoma: a systematic review","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; London Health Sciences Centre; Western University","funders":"","keywords":"Orthopedic surgery; Quality of life (healthcare); Multidisciplinary approach; Psychological intervention; Narrative review; MEDLINE; Retrospective cohort study; Systemic therapy","score_opus":0.03306252715342925,"score_gpt":0.41246896238881975,"score_spread":0.3794064352353905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415229284","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024454074,0.99663794,0.000077234035,0.00013996298,0.000042707554,0.000200604,0.00029271952,0.000004708131,0.00015872276],"genre_scores_gemma":[0.051284153,0.9464783,0.0006112125,0.000445646,0.000093436,0.0006632261,0.0003436737,0.0000040365485,0.00007629399],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9942932,0.00196446,0.002137169,0.00045621642,0.00097519375,0.00017381359],"domain_scores_gemma":[0.97969556,0.013395031,0.005089262,0.00022248473,0.0013687077,0.00022881539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052492293,0.0011983167,0.0074101966,0.0063930927,0.0005242065,0.0017635293,0.0014014369,0.0015333717,0.002546443],"category_scores_gemma":[0.027563553,0.00080987974,0.008462587,0.0074982145,0.0006655967,0.0013975843,0.000978281,0.00093619275,0.00013851073],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030440144,0.00002246658,0.002863555,0.95706844,0.020611616,0.00009761644,0.000110566456,0.000115956886,0.00008764863,0.00009295112,0.00068001775,0.017944846],"study_design_scores_gemma":[0.0008862093,0.00051989924,0.020049695,0.73854834,0.22816525,0.0006927245,0.00035674285,0.00024596587,0.00021481412,0.0002942308,0.009965363,0.00006078893],"about_ca_topic_score_codex":0.007523249,"about_ca_topic_score_gemma":0.021079177,"teacher_disagreement_score":0.007523249,"about_ca_system_score_codex":0.0025660098,"about_ca_system_score_gemma":0.006978815,"threshold_uncertainty_score":0.027760923},"labels":[],"label_agreement":null},{"id":"W4415459306","doi":"10.1177/17588359251367315","title":"A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Nivolumab; Retrospective cohort study; Myeloid; Immune system; Immunotherapy; Programmed cell death 1","score_opus":0.008752935889310028,"score_gpt":0.29337686642125704,"score_spread":0.284623930531947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415459306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992654,0.00024974637,0.00007266197,0.000010981309,0.0000022589788,0.000009103555,0.00024544806,0.0000019835668,0.00014246293],"genre_scores_gemma":[0.9996141,0.00005412245,0.000043412863,0.000009266424,0.000004049023,0.000008139302,0.00023931765,7.230865e-7,0.000026853513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994361,0.000126375,0.00010628697,0.00015940247,0.000101473524,0.00007032044],"domain_scores_gemma":[0.997877,0.0004939305,0.0011122469,0.0001699639,0.00015073901,0.00019612412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006767678,0.00016083388,0.00033912828,0.000624448,0.00030296243,0.00034057526,0.0002733563,0.0002565315,0.000981718],"category_scores_gemma":[0.0017303474,0.0002530145,0.00035776803,0.00088035123,0.00030213746,0.00036965465,0.00028693807,0.000294696,0.00014387837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092405186,0.000008750362,0.99922526,0.000006268858,0.000025267522,0.0000874879,0.00001352633,0.000017195543,0.0001326675,0.0000052128657,0.000025696261,0.00036008123],"study_design_scores_gemma":[0.000017157889,0.00023486714,0.99787235,0.0000060031443,0.000053428394,0.0011092915,0.0001082293,0.00020448156,0.00014487129,0.0000120818495,0.00023392159,0.0000033374952],"about_ca_topic_score_codex":0.0016950963,"about_ca_topic_score_gemma":0.0020228731,"teacher_disagreement_score":0.0016950963,"about_ca_system_score_codex":0.0003434319,"about_ca_system_score_gemma":0.00040521842,"threshold_uncertainty_score":0.0035791397},"labels":[],"label_agreement":null},{"id":"W4415651750","doi":"10.1177/17588359251386765","title":"Prognostic utility of inflammatory indices and circulating nucleic acids for neoadjuvant chemotherapy outcomes in breast cancer: a systematic review","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemotherapy; Nucleic acid; MEDLINE; Breast cancer; Value (mathematics); Circulating tumor DNA","score_opus":0.024086511766256227,"score_gpt":0.40564639681080533,"score_spread":0.38155988504454913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415651750","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022191145,0.9960431,0.00017966822,0.00025512002,0.00006728209,0.00029783658,0.00074159354,0.0000084777475,0.00018782975],"genre_scores_gemma":[0.04656495,0.9501104,0.0008560297,0.00062539574,0.000089220375,0.0010337153,0.0005846031,0.000008160323,0.00012751351],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.992018,0.0026545431,0.00320926,0.00071640406,0.0011490576,0.00025274462],"domain_scores_gemma":[0.9546535,0.034323007,0.0075816824,0.00055563723,0.0025711523,0.00031504355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009434966,0.0015258756,0.008650011,0.009971667,0.00055184425,0.0025921243,0.0018661604,0.0017090093,0.002962067],"category_scores_gemma":[0.051969018,0.0009815239,0.009127565,0.0099454755,0.00095303357,0.0020470521,0.0014913859,0.000964554,0.00025287026],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020271527,0.0000100738,0.0023027984,0.96593785,0.015103446,0.00006971189,0.00013383757,0.00011500554,0.0001040451,0.00010975538,0.00058875646,0.015322004],"study_design_scores_gemma":[0.00027542422,0.00022753651,0.009396539,0.81512064,0.16569531,0.00034040335,0.00025948338,0.0001569302,0.00017522663,0.00034403036,0.007958731,0.000049733124],"about_ca_topic_score_codex":0.008232289,"about_ca_topic_score_gemma":0.022525212,"teacher_disagreement_score":0.009971667,"about_ca_system_score_codex":0.0032450825,"about_ca_system_score_gemma":0.011089493,"threshold_uncertainty_score":0.049897492},"labels":[],"label_agreement":null},{"id":"W4415733338","doi":"10.1177/17588359251387393","title":"Antibody–drug conjugates versus docetaxel for previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Docetaxel; Randomized controlled trial; Overall survival; Lung; Lung cancer; Subgroup analysis; Clinical trial","score_opus":0.055942934672215214,"score_gpt":0.5015752000993928,"score_spread":0.4456322654271776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415733338","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030021614,0.99512994,0.0005166007,0.00014584807,0.000120312565,0.00054254,0.0003309285,0.000019334771,0.00019244365],"genre_scores_gemma":[0.111996666,0.87993735,0.0033065581,0.0008725729,0.0002525231,0.0025825796,0.0007356636,0.000028110055,0.00028809495],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9846793,0.00810675,0.0042107217,0.0012056007,0.0014649061,0.00033261234],"domain_scores_gemma":[0.9764504,0.017457156,0.003954701,0.000503686,0.0013823423,0.00025159685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018770607,0.0028352477,0.023436224,0.0069296015,0.0006358805,0.0031036779,0.0023728104,0.002286541,0.003644643],"category_scores_gemma":[0.039200027,0.0013304732,0.037986517,0.007493085,0.0008073447,0.0020577612,0.0013778965,0.0020031463,0.00026635418],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023953144,0.00003332012,0.0015894164,0.54143155,0.44094136,0.00008212089,0.00006693594,0.0005516405,0.00015044151,0.00016626698,0.00046866215,0.012122939],"study_design_scores_gemma":[0.0012137438,0.00030372763,0.0017283143,0.040298495,0.95417887,0.00006925809,0.00003899618,0.00024006654,0.000105244115,0.00024228213,0.0015584265,0.000022545295],"about_ca_topic_score_codex":0.005528337,"about_ca_topic_score_gemma":0.011807951,"teacher_disagreement_score":0.023436224,"about_ca_system_score_codex":0.0035082977,"about_ca_system_score_gemma":0.0045274603,"threshold_uncertainty_score":0.09926963},"labels":[],"label_agreement":null},{"id":"W4416554337","doi":"10.1177/17588359251339939","title":"Characteristics of <i>KRAS</i> WT pancreatic adenocarcinomas: results of a large French multicentric cohort","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cohort; Targeted therapy; Mutation; Gene; Pancreatic cancer; Cohort study; MEDLINE","score_opus":0.005081101432230146,"score_gpt":0.3071218625817954,"score_spread":0.30204076114956524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416554337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983767,0.00032688866,0.00021891625,0.000034868754,0.000003449032,0.000016200358,0.00076367497,0.000009651156,0.0002495614],"genre_scores_gemma":[0.9980726,0.00022841486,0.00015544145,0.000040445553,0.000012075772,0.000019718169,0.0012782353,0.000009641317,0.00018344655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893445,0.00022706114,0.000095933814,0.0004258298,0.00014648918,0.00017016477],"domain_scores_gemma":[0.9984101,0.00030854362,0.00045647917,0.000279178,0.00025578434,0.00028991458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016917096,0.0006636787,0.0007372666,0.002196328,0.0007691911,0.0010800734,0.00050468673,0.00065311836,0.0020879663],"category_scores_gemma":[0.002241786,0.00047111083,0.0009605304,0.0015519734,0.00048295787,0.0005248687,0.0007775927,0.00035182462,0.00052480114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018422455,0.000028521243,0.995817,0.000015204658,0.00013209123,0.00048605952,0.00022337754,0.000069083806,0.00058068725,0.000019450801,0.00019784436,0.002246399],"study_design_scores_gemma":[0.0000113473825,0.00013849884,0.99749005,0.000008383408,0.00005604795,0.0013589629,0.00023739404,0.000104530256,0.000073181414,0.000012097439,0.0005008754,0.000008765023],"about_ca_topic_score_codex":0.016287336,"about_ca_topic_score_gemma":0.010947639,"teacher_disagreement_score":0.016287336,"about_ca_system_score_codex":0.0010207619,"about_ca_system_score_gemma":0.00058141217,"threshold_uncertainty_score":0.03238505},"labels":[],"label_agreement":null},{"id":"W7116844250","doi":"10.1177/17588359251385410","title":"TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with <i>EGFR</i> -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"Daiichi Sankyo Europe; National Cancer Institute; Eli Lilly Japan; Pfizer Japan; EMD Serono; Daiichi-Sankyo; Eli Lilly and Company; Ono Pharmaceutical; Sanofi; Apollomics; Yuhan; Taiho Pharmaceutical; Boehringer Ingelheim Japan; BeiGene; Chugai Pharmaceutical; Nihon Medi-Physics; Astellas Pharma; AstraZeneca; Novocure; Genomic Health; GlaxoSmithKline; Amgen; Pfizer; Les Laboratories Pierre Fabre; Bristol-Myers Squibb","keywords":"Osimertinib; Lung cancer; Chemotherapy; Disease; Randomized controlled trial; Phases of clinical research; Clinical trial; Lung disease","score_opus":0.012525595294375842,"score_gpt":0.3687785906845456,"score_spread":0.35625299539016975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116844250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860405,0.0013977785,0.0007406129,0.00053593033,0.000476132,0.007857452,0.0011029345,0.0001485515,0.0017000397],"genre_scores_gemma":[0.97871345,0.0015757926,0.0023013796,0.001604756,0.0003988457,0.009370824,0.0018742059,0.000044858352,0.004115884],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991854,0.00040776882,0.000041726104,0.00015836259,0.000053456217,0.0001533498],"domain_scores_gemma":[0.99869436,0.00024353391,0.00026446473,0.000091444876,0.0000681901,0.00063799496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028399483,0.002672359,0.0030991088,0.0005678997,0.0004990936,0.0015867098,0.0015363452,0.0021557729,0.006594178],"category_scores_gemma":[0.0016520087,0.0010551106,0.00238165,0.00050048303,0.0019519336,0.0015986275,0.00060586206,0.0036998559,0.0013071696],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9610846,0.021598006,0.0008868219,0.0003200845,0.00062677206,0.00004509429,0.00007768594,0.0005528823,0.0042355726,0.00015397124,0.00068005174,0.009738416],"study_design_scores_gemma":[0.87872356,0.11897577,0.00085509557,0.000012785539,0.00022020972,0.000028777478,0.000022133205,0.00036225776,0.00033558416,0.00009475937,0.0003570349,0.000011951019],"about_ca_topic_score_codex":0.001496404,"about_ca_topic_score_gemma":0.0031045172,"teacher_disagreement_score":0.006594178,"about_ca_system_score_codex":0.001432718,"about_ca_system_score_gemma":0.0023912042,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null}]}